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ABSTRACT

Compositions and methods for reducing the level of nomico
tine and N'-nitrosonornicotine (NNN) inNicotiana plants and
plant parts thereof are provided. The compositions comprise

isolated polynucleotides and polypeptides for cytochrome
P450s that are involved in the metabolic conversion of nico

tine to nornicotine in these plants. Expression cassettes, vec

tors, plants, and plant parts thereof comprising inhibitory
sequences that target expression or function of the disclosed

cytochrome P450 polypeptides are also provided. Methods
for the use of these novel sequences to inhibit expression or

function of cytochrome P450 polypeptides involved in this
metabolic conversion are also provided. The methods ?nduse

in the production of tobacco products that have reduced levels
of nornicotine and its carcinogenic metabolite, NNN, and
thus reduced carcinogenic potential for individuals consum
ing these tobacco products or exposed to secondary smoke
derived from these products.

4 Claims, 3 Drawing Sheets
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ALTERATION OF TOBACCO ALKALOID
CONTENT THROUGH MODIFICATION OF
SPECIFIC CYTOCHROME P450 GENES

Which eliminate the mixing of combustion gases With curing
air, thereby reducing TSNAs in tobaccos cured in this manner
(Boyette & Hamm (2001) Rec. Adv. Tob. Sci. 27:17-22.). In
contrast, in air-cured Burley tobaccos, TSNA formation pri
marily proceeds through a reaction of tobacco alkaloids With
nitrite, a process catalyZed by leaf-borne microbes (Bush et
al. (2001) Rec. Adv. Tob. Sci. 27:23-46). Thus far, attempts to
reduce TSNAs through modi?cation of curing conditions
While maintaining acceptable quality standards have not been

CROSS-REFERENCE TO RELATED
APPLICATIONS

This application claims the bene?t of US. Provisional
Application No. 60/987,243, ?led Nov. 12, 2007, the content
of Which is hereby incorporated in its entirety by reference

successful for air-cured tobaccos.

herein.

In Burley tobacco plants, a positive correlation exists
betWeen the nornicotine content of a leaf and an amount of

REFERENCE TO SEQUENCE LISTING

NNN that accumulates in the cured leaf (Bush et al. (2001)
Rec. Adv. Tob. Sci, 27:23-46; and Shi et al. (2000) Tob. Chem.

SUBMITTED ELECTRONICALLY

Res. Conf 54: Abstract 27). HoWever, keeping nornicotine

An of?cial copy of the Sequence Listing is submitted elec

levels at a minimum is dif?cult in Burley tobacco plants
because of conversion. Plant breeders and seed producers are

tronically via EFS-Web as an ASCII formatted Sequence
Listing With a ?le named “362493SequenceListing.txt,” cre
ated on Nov. 11, 2008, and having a siZe of 137 kb and is ?led

concurrently With the speci?cation. The Sequence Listing

20

traditionally responsible for minimiZing the number of Bur
ley tobacco plants that accumulate high levels of nomicotine.
Though the percentage of converters that are ultimately
groWn in ?elds are reduced through roguing converters during
propagation of seed stocks. Unfortunately, this process is

contained in this ASCII formatted document is part of the

speci?cation and is herein incorporated by reference in its

entirety.

costly, time-consuming and imperfect.
FIELD OF THE INVENTION

25

121:343-344; Burke & Jeffrey (1958) Tob. Sci. 2:139-141;

The present invention relates to compositions and methods
for reducing the level of nornicotine and its metabolite, N'-ni
trosonornicotine (NNN), in a plant that is a member of the

genus Nicoliana, particularly compositions and methods for

30

inhibiting expression or function of a cytochrome P450

polypeptide involved in the metabolic conversion of nicotine

and Man et al. (1964) Crop Sci. 4:349-353). The nature ofthis
gene, hoWever, is currently unknoWn. In the simplest of sce
narios, the conversion locus may represent a nonfunctional
nicotine N-demethylase gene that regains its function in con
verters, possibly through the mobilization of a mutation-in

ducting transposable element. Alternatively, the converter

to nomicotine.

BACKGROUND OF THE INVENTION

Once a plant converts, the high nornicotine trait is inherited
as a single dominant gene (Grif?th et al. (1955) Science

35

locus may encode a protein that initiates a cascade of events
that ultimately enables converters to metaboliZe nicotine to

nornicotine, meaning that multiple genes may be involved.
A predominant alkaloid found in commercial tobacco vari

eties is nicotine, typically accounting for 90%-95% of the
total alkaloid pool. The remaining alkaloid fraction is prima
rily three additional pyridine alkaloids: nomicotine, ana
basine and anatabine. Nomicotine is generated directly from
nicotine by nicotine N-demethylase. Nomicotine usually rep
resents less than 5% of the total pyridine alkaloid pool. HoW
ever, tobacco plants that initially produce very loW amounts
of nornicotine can give rise to progeny that metabolically
“convert” a large percentage of leaf nicotine to nomicotine.
This process is termed “conversion.” In tobacco plants that

Regardless of Whether there are one or many genes asso

ciated With conversion, the gene(s) encoding polypeptides
having nicotine demethylase activity play a pivotal role in this
40

and identi?cation of this enzyme, there is some evidence that

a member of the cytochrome P450 superfamily of monooxy
genases may be involved (Hao &Yeoman (1996)Phylochem.
45

Unfortunately, these studies are not conclusive, as classic
50

to genetic conversion, With rates as high as 20% per genera
tion observed in some cultivars.

During curing and processing of the tobacco leaf, a portion
of the nornicotine is metaboliZed to NNN, a tobacco-speci?c

55

nitrosamine (TSNA) alleged to be carcinogenic in laboratory
animals (Hecht & Hoffmann (1990) Cancer Surveys 8:273

tobacco,” CORESTA Meeting, Agro-Phyto Groups, SuZhou,
China). The combustion gases, hoWever, can be eliminated
When curing barns are retro?tted With heat-exchangers,

P450 inhibitors, such as carbon monoxide and tetcylasis, fail
to loWer enZyme activity at rates comparable to other reported
P450-mediated reactions (Chelvarajan et al. (1993) J. A gric.

Food Chem. 41:858-862).
Furthermore, cytochrome P450s are ubiquitous, trans
membrane proteins that participate in metaboliZing a Wide
range of compounds (revieWed by Schuler (1996) Cril. Rev
Plant Sci. 15:235-284; and Schuler & Werck-Reichhart

(2003) Annu. Rev Plant Biol. 54:629-667). Examples ofbio
chemical reactions mediated by cytochrome P450s include

294; and Hoffmann et al. (1994) J. Toxicol. Environ. Health

41:1-52; Hecht (1998) Chem. Res. Toxicol. 11:559-603). In
?ue-cured tobaccos, TSNAs predominantly form through a
reaction of alkaloids With minute amounts of nitrogen oxides
present in combustion gases in a direct-?red heating systems
used in traditional curing barns (Peele & Gentry (1999) “For
mation of tobacco-speci?c nitrosamines in ?ue-cured

41:477-482; Hao &Yeoman (1996) Phylochem. 42:325-329;
Chelvarajan et al. (1993) .1. Agric, Food Chem. 41:858-862;
and Hao & Yeoman (1998) .1. Plant Physiol. 152:420-426).

have genetically converted (i.e., “converters”), the great
majority of nornicotine production occurs during senescence
and curing of a mature leaf (Wemsman & MatZinger (1968)
Tob. Sci. 12:226-228). Burley tobaccos are particularly prone

process. Although the inability to purify active nicotine
N-demethylase from crude extracts has impeded the isolation

hydroxylations, demethylations and epoxidations. In plants,
60

cytochrome P450 gene families are very large. For example,
total genome sequence examination revealed 272 predicted
cytochrome P450 genes in Arabidopsis and at least 455
unique cytochrome P450 genes in rice (see, e.g., Nelson et al.

65

chrome P450s have been implicated in the conversion of

(2004) Plant Physiol. 135(2):756-772). Even though cyto
nicotine to nomicotine, identi?cation of key participating
members of this protein family remains a challenge.

US 8,124,851 B2
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at 216 is not tyrosine, the residue at 245 is not a tyrosine, and
the residue at 466 is not valine.
In a second aspect, the present invention is summariZed as

Aside from serving as a precursor for NNN, recent studies

suggest that the nornicotine found in tobacco products has
undesirable health consequences. For example, Dickerson &
Janda demonstrated that nornicotine causes aberrant protein
glycosylation Within a cell (Dickerson & Janda (2002) Proc.
Natl. Acad. Sci. USA 99: 15084-15088). Likewise, concentra
tions of nornicotine-modi?ed proteins Were much higher in

an expression cassette comprising a polynucleotide encoding
an amino acid sequence of SEQ ID N012 operably linked to
a promoter that is functional in a plant cell. The present

tent in tobacco varieties, particularly Burley tobacco plants,

invention provides an expression cassette comprises a poly
nucleotide comprising a nucleic acid sequence of SEQ ID
N013, or a fragment of at least 25 contiguous nucleic acids
thereof, operably linked to a promoter that is functional in a
plant cell. Also provided is an isolated polynucleotide com
prising at least 25 nucleotides of a nucleic acid sequence of
SEQ ID N013. Further provided is an isolated polypeptide
comprising an amino acid sequence selected from the group
consisting of SEQ ID N012, 5-12 and 14-24. In one embodi

are therefore desirable. Such methods Would not only help

ment of the second aspect, the isolated polypeptide comprises

plasma of smokers compared to nonsmokers. Furthermore,
nornicotine can covalently modify commonly prescribed ste
roid drugs such as prednisone, Which can alter both the e?i

cacy and toxicity of these drugs.
In vieW of the di?iculties associated With conversion, as
Well as the undesirable health effects of nornicotine accumu

lation, improved methods for reducing the nornicotine con

ameliorate the potential negative health consequences of the

an amino acid sequence 99% identical to SEQ ID N012, such

nornicotine per se as described above, but also help to reduce
NNN levels.

that it is capable of converting nicotine to nornicotine in green
leaves of tobacco.
20

Compositions and methods are provided for reducing the
nornicotine content in plants that are members of the genus

Nicoliana. Compositions include isolated cytochrome P450

In a third aspect, the present invention is summariZed as a

plant of the genus Nicoliana or a plant part thereof comprising
an expression cassette, the cassette encoding SEQ ID N012, a
fragment thereof, or a complement of either. Also provided is
a transgenic Nicoliana plant having a loWer level of nicotine

SUMMARY OF THE INVENTION

25

to nornicotine conversion rate in green leaves compared to a

polynucleotides and polypeptides that are involved in conver

non-transgenic plant, the plant comprising an exogenous

sion of nicotine to nornicotine in plants, particularly Nicoti

nucleic acid construct comprising a promoter capable of
functioning in a plant cell operably linked to a polynucleotide
having a ?rst nucleic acid sequence comprising a region of
betWeen about 100 nucleic acids and about 350 nucleic acids
of a green-leaf tobacco nicotine demethylase sequence
encoding an amino acid sequence of SEQ ID N012 and a
second nucleic acid sequence capable of forming a double
stranded RNA With the ?rst sequence. Further provided is a
transgenic Nicoliana plant having a loWer level of nicotine to

ana species. Isolated polynucleotides include those that com
prise a nucleic acid sequence as set forth in SEQ ID N01 1, 3
or 4, a nucleic acid sequence encoding a polypeptide as set

30

forth in SEQ ID N012, 5-12, 14-24, and fragments and vari
ants thereof. Isolated polypeptides of the invention include
those that comprise an amino acid sequence as set forth in
SEQ ID N012, 5-12 or 14-24, an amino acid sequence

encoded by the nucleic acid sequence set forth in SEQ ID N01
1, 3 or 4, and fragments and variants thereof.

35

nornicotine conversion rate in green leaves compared to a

non-transgenic plant, the plant comprising an exogenous

In a ?rst aspect, the present invention is summarized as
polynucleotides that can suppress expression of a nicotine

demethylase involved in the metabolic conversion of nicotine
to nornicotine in a plant, including the nicotine demethylases
of the present invention. The present invention provides an

40

isolated polynucleotide having a promoter capable of func
tioning in a plant cell operably linked to a nucleic acid
sequence comprising a region of betWeen about 100 nucleic
acids and about 350 nucleic acids of SEQ ID N01 1 obtained

45

from a sequence selected from the group of nucleic acids at

nucleic acid construct comprising a promoter capable of
functioning in a plant cell operably linked to a polynucleotide
having a ?rst nucleic acid sequence comprising a region of
betWeen about 100 nucleic acids and about 350 nucleic acids
of a green-leaf tobacco nicotine demethylase sequence hav
ing the nucleic acid sequence of SEQ ID N013 and a second
nucleic acid sequence capable of forming a double stranded
RNA With the ?rst sequence is provided. Also provided is a
transgenic Nicoliana plant having a loWer level of nicotine to

position 253, 353, 647, 733, 1050, 1397 and combinations

nornicotine conversion rate in green leaves compared to a

thereof. The present invention also provides an isolated poly

non-transgenic plant, the plant comprising an exogenous

nucleotide comprising a nucleic acid sequence encoding a

green-leaf nicotine demethylase, Where the amino acid

50

sequence of the encoded nicotine demethylase has a substi
tution at an amino acid residue in a position selected from the

group consisting ofresidues 235, 449, 174, 410, 224, 72, 143
and 422, Where the numbering is according to SEQ ID N012.
Also provided is an isolated polynucleotide comprising a
promoter capable of functioning in a plant cell operably

55

linked to a nucleic acid sequence comprising a region of
betWeen about 100 nucleic acids and about 350 nucleic acids

In a fourth aspect, the present invention is summariZed as a
nicotine to nornicotine conversion rate in green leaves com
60

sequence as set forth in SEQ ID N012 With a mutation at a

position selected from the group consisting of residues 85,
118, 216, 245 and 466, Where the residue at 85 is not an
isoleucine, the residue at 118 is not an asparagine, the residue

ing a nucleic acid sequence of SEQ ID N014 and a second
nucleic acid sequence capable of forming a double stranded
RNA With the ?rst sequence.

seed of a transgenic Nicoliana plant having a loWer level of

of SEQ ID N014. Further provided is an isolated polynucle
otide encoding an amino acid sequence as set forth in SEQ ID
N012 With a mutation of a residue that differs from the other
P450 polypeptides to a conserved residue. Alternatively pro
vided is an isolated polynucleotide encoding an amino acid

nucleic acid construct comprising a promoter capable of
functioning in a plant cell operably linked to a polynucleotide
having a ?rst nucleic acid sequence comprising a region of
betWeen about 100 nucleic acids and about 350 nucleic acids
of a green-leaf tobacco nicotine demethylase sequence hav

65

pared to a non-transgenic plant, the plant comprising a heter
ologous promoter capable of functioning in a plant cell oper
ably linked to a polynucleotide having a ?rst nucleic acid
sequence comprising a region of betWeen about 100 nucleic
acids and about 350 nucleic acids of a green-leaf tobacco
nicotine demethylase sequence having an amino acid
sequence of SEQ ID N014 and a second nucleic acid
sequence capable of forming a double stranded RNA With the

US 8,124,851 B2
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?rst sequence. Also provided is a tissue culture of regenerable
tobacco cells comprising a plant cell that comprises a ?rst
polynucleotide having a fragment of the nucleic acid
sequence of SEQ ID NO: 1, 3 or 4 and a second polynucle
otide capable of forming a double stranded RNA With the
?rst.

functional

CYP82E5v2,

Where

the

nonfunctional

CYP82E5v2 has a substitution at an amino acid residue in a

position selected from the group consisting of residues 235,
449, 174, 410, 224, 72, 143 and 422, Where the numbering is
according to SEQ ID NO:2; and b) reducing the level of
nornicotine in a plant part derived from a plant of the genus
Nicoliana. The present invention also provides a method for

In a ?fth aspect, the present invention is summarized as a

tobacco product comprising a transgenic Nicoliana plant cell

reducing the carcinogenic potential of a tobacco product, the

having a loWer level of nicotine to nomicotine conversion rate

method comprising preparing the tobacco product by a)

in green leaves compared to a non-transgenic plant, the plant
cell comprising a heterologous promoter capable of function
ing in a plant cell operably linked to a polynucleotide having

groWing a transgenic tobacco plant, Where the plant com
prises a plant part that comprises a fragment of a green-leaf
nicotine demethylase operably linked to a heterologous pro
moter and the fragment comprises at least 25 contiguous
nucleic acids from a polynucleotide encoding a polypeptide
selected from the group consisting of SEQ ID NOs:2 and
5-12; and b) preparing a tobacco product from the tobacco
plant part. Further, the present invention provides a method of

a ?rst nucleic acid sequence comprising a region of betWeen
about 100 nucleic acids and about 350 nucleic acids of a

green-leaf tobacco nicotine demethylase sequence having a
nucleic acid sequence of SEQ ID NO4 and a second poly
nucleotide capable of forming a double stranded RNA With
the ?rst. Also provided is a tobacco cell having a genome
altered to inhibit the expression of at least a green-leaf nico
tine demethylase, Where the cell is homozygous for a muta

reducing the conversion of nicotine to nornicotine in a Nic

oliana plant comprising: a) transforming a Nicoliana plant
20

tion in the gene encoding the green-leaf nicotine demethy
lase. Further provided is a tobacco cell comprising a

trans gene containing green-leaf nicotine demethylase nucleic
acid sequence that ?anks a selectable marker gene, Where the

selectable marker gene disrupts the nicotine demethylase
gene, thereby producing a tobacco cell Where the endogenous

25

sequence; and b) regenerating a transgenic Nicoliana plant.

green-leaf nicotine demethylase gene has been disrupted.

In a seventh aspect, the present invention is summarized as

Alternatively provided is a tobacco cell comprising a trans

gene containing green-leaf nicotine demethylase nucleic acid
sequence that ?anks a selectable marker gene, Where the

30

selectable marker gene disrupts the nicotine demethylase
gene, thereby producing a tobacco cell Where the endogenous
green-leaf nicotine demethylase gene has been disrupted.

a method of screening for a green-leaf nicotine demethylase
sequence comprising a) obtaining a nucleic acid sequence
that has at least 200 nucleic acids of sequence identity With

SEQ ID NO: 1; and b) identifying a codon sequence encoding
for a stop codon at position 422 of an encoded polypeptide,
Where the numbering is according to SEQ ID N012. Also
provided is a method of screening for green-leaf nicotine

In a sixth aspect, the present invention is summarized as a

method for reducing nornicotine levels in a plant part derived
from a plant of the genus Nicoliana, the method comprising a)
inhibiting expression of a nicotine demethylase, Where the

With an nucleic acid construct comprising a promoter capable
of functioning in a plant cell operably linked to a polynucle
otide having a ?rst nucleic acid sequence comprising a region
of betWeen 100 nucleic acids and about 350 nucleic acids of
SEQ ID NO: 1, 3 or 4 and a second nucleic acid sequence
capable of forming a double stranded RNA With the ?rst

35

demethylase sequence comprising a) obtaining a nucleic acid
sequence that has at least 200 nucleic acids of sequence

identity With SEQ ID NO: 1; and b) identifying a codon

nicotine demethylase has an amino acid sequence set forth in
40

sequence encoding for a codon that is not a proline at position
449 of an encoded polypeptide, Where the numbering is
according to SEQ ID N012. Further provided is a method for
identifying a tobacco plant With loW levels of nornicotine, the
method comprising a) obtaining a DNA sample from a

prising a) groWing a transgenic tobacco plant, Where the plant

tobacco plant of interest; and b) screening the sample for a

having a plant part that comprises an expression cassette
comprising a heterologous promoter and a nicotine demethy
lase, Where the nicotine demethylase has an amino acid
sequence selected from the group consisting of SEQ ID
NOs:2 and 5-12; and b) preparing a tobacco product from the
tobacco plant part. Further provided is a method for reducing
nomicotine levels in a tobacco product, the method compris

45

mutation in SEQ ID NO: 1. The present invention also pro
vides a method for reducing the level of nomicotine in a plant
part derived from a plant of the genus Nicoliana, the method

the group consisting of SEQ ID NOs: 2 and 5-12; and b)
reducing nornicotine levels in a plant part derived from a plant
of the genus Nicoliana. Also provided is a method for reduc
ing nomicotine levels in a tobacco product, the method com

comprising a) inhibiting expression of a CYP82E4v2 nico
tine demethylase and CYP82E5v2 nicotine demethylase; and
b) reducing the level of nomicotine in a plant part derived
50

from a plant of the genus Nicoliana. Also included is tobacco
plant material comprising a polypeptide With an amino acid
sequence of SEQ ID NO: 13 having a mutation at a position
selected from the group consisting of residues 458, 364, 329
and combinations thereof. Further included is tobacco plant

55

material comprising a CYP82E4v2 having a mutation at a

ing a) groWing a transgenic tobacco plant, Where the plant has
a plant part that comprises an antibody that speci?cally binds
a polypeptide With an amino acid sequence selected from the

group consisting of SEQ ID NOs:2 and 5-12; and b) preparing
a tobacco product from the tobacco plant part. Alternatively
provided is a method for reducing nomicotine levels in a

tobacco product, the method comprising a) groWing a trans
genic tobacco plant, Where the plant has a plant part that
comprises a fragment of a green-leaf nicotine demethylase
operably linked to a heterologous promoter and the fragment

position selected from the group consisting of residues 458,
364, 329 and combinations thereof, Where the numbering
60

has at least 25 contiguous nucleic acids from a polynucleotide

encoding a polypeptide selected from the group consisting of
SEQ ID NOs:2 and 5-12; and b) preparing a tobacco product
from the tobacco plant part. Also provided is a method for
reducing nornicotine levels in a plant part derived from a plant

of the genus Nicoliana, the method comprising a) modifying
the functional CYP82E5v2 allele to change alleles to a non

corresponds to SEQ ID NO: 13. Also included is tobacco
plant material comprising a CYP82E4v2 having a mutation at
residue 376, Where the residue is not valine and the number

ing of residues corresponds to SEQ ID NO: 13.
BRIEF DESCRIPTION OF DRAWINGS
65

FIG. 1A-C shoW an amino acid sequence alignment of

CYP82E2 gene family members that have been assayed for
nicotine demethylase activity in yeast and/ or transgenic

US 8,124,851 B2
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plants. Sequences in italics and underlined are positive for

nicotine

demethylase

activity

(CYP82E4v2

and

CYP82E5v2); sequences titled in black failed to show activ
ity in an assay. Residues that differ among the members are

shaded in grey. In FIG. 1, CYP82E4v2 is set forth in SEQ ID
NO: 13; CYP82E4v6 is set forth in SEQ ID N0:26;
CYP82E4v12 is set forth in SEQ ID N0:27; 58-166 is set
forth in SEQ ID N0:28; CYP82E3 is set forth in SEQ ID
N0:29; CYP82E2v1 is set forth in SEQ ID N0130;
CYP82E2v2 is set forth in SEQ ID N031; and CYP82E5v2
is set forth in SEQ ID N012.
DESCRIPTION OF THE NUCLEIC ACID

SEQUENCES
SEQ ID NO: 1 sets forth a nucleic acid sequence of a

coding region of CYP82E5v2.
SEQ ID NO:2 sets forth an amino acid sequence of a
CYP82E5v2.
SEQ ID NO:3 sets forth a nucleic acid sequence of an

20

intron of CYP82E5v2.
SEQ ID NO:4 sets forth a nucleic acid sequence of a

genomic CYP82E5v2.
SEQ ID N0:5 sets forth an amino
CYP82E5v2 P235S.
SEQ ID NO:6 sets forth an amino
CYP82E5v2 P449L.
SEQ ID NO:7 sets forth an amino
CYP82E5v2 S174L.
SEQ ID NO:8 sets forth an amino
CYP82E5v2 A410V.
SEQ ID N029 sets forth an amino
CYP82E5v2 M2241.
SEQ ID N0:10 sets forth an amino
CYP82E5v2 P72L.
SEQ ID N0:11 sets forth an amino
CYP82E5v2 L143F.
SEQ ID N0:12 sets forth an amino

acid sequence of a
25

acid sequence of a
acid sequence of a
30

sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa
sequence ofa

primer E5Gen_R1.
SEQ ID N0:42 sets forth a nucleic acid sequence of a

acid sequence of a

primer E5Gen_F2.

acid sequence of a

primer E5Gen_R2.

SEQ ID N0z43 sets forth a nucleic acid sequence of a
35

SEQ ID N0:44 sets forth a nucleic acid sequence of a

acid sequence of a

primer E4Rt_F.

acid sequence of a

primer E4Rt_R.

acid sequence of a 40

primer E5Rt_F.

acid sequence of a

primer E5Rt_R.

acid sequence of a

primer G3PDH_F.

SEQ ID N0:45 sets forth a nucleic acid sequence of a
SEQ ID N0:46 sets forth a nucleic acid sequence of a
SEQ ID N0:47 sets forth a nucleic acid sequence of a
SEQ ID N0:48 sets forth a nucleic acid sequence of a
45

SEQ ID N0:49 sets forth a nucleic acid sequence of a

acid sequence of a

primer G3PDH_R.

acid sequence of a

coding region of CYP82E4v2 and the encoded protein (i.e.,
SEQ ID N0:13).

SEQ ID N0:50 sets forth a nucleic acid sequence of a

acid sequence of a 50

DEFINITIONS
forth an amino acid sequence of a

The present invention includes compositions and methods
for inhibiting expression or function of nicotine demethylase

forth an amino acid sequence of a
55

polypeptides that are involved in the metabolic conversion of
nicotine to nornicotine in a plant, particularly plants of the
Nicoliana genus, including tobacco plants of various com
mercial varieties.

60

de?ned as any method knoWn in the art or described herein,

forth an amino acid sequence of a
forth an amino acid sequence of a

CYP82E4v2 W329Stop.
SEQ ID N0:23 sets
CYP82E4v2 V376M.
SEQ ID N0:24 sets
CYP82E4v2 D171N.
SEQ ID N0:25 sets
CYP82E4.
SEQ ID N0:26 sets
CYP82E4v6.

sequence ofa

SEQ ID N0:41 sets forth a nucleic acid sequence of a
acid sequence of a

CYP82E4v2 R169Q.
SEQ ID N0:19 sets
CYP82E4v2 G459R.
SEQ ID N0:20 sets
CYP82E4v2 E296K.
SEQ ID N0:21 sets
CYP82E4v2 T4271.
SEQ ID N0:22 sets

sequence ofa

primer E5 Gen_F1.

CYP82E5v2 W422Stop.
SEQ ID N0:13 sets forth an amino
CYP82E4v2.
SEQ ID N0:14 sets forth an amino
CYP82E4v2 P458S.
SEQ ID N0:15 sets forth an amino
CYP82E4v2 K364N.
SEQ ID N0:16 sets forth an amino
CYP82E4v2 P38L.
SEQ ID N0:17 sets forth an amino
CYP82E4v2 E201K.
SEQ ID NO: 18 sets forth an amino

SEQ ID N0:27 sets forth an amino acid
CYP82E4v12.
SEQ ID N0:28 sets forth an amino acid
58-166.
SEQ ID N0:29 sets forth an amino acid
CYP82E3.
SEQ ID N0130 sets forth an amino acid
CYP82E2v1.
SEQ ID N0131 sets forth an amino acid
CYP82E2v2.
SEQ ID N0z32 sets forth a nucleic acid
forWard primer for exon 1 of CYP82E4v2.
SEQ ID N0z33 sets forth a nucleic acid
reverse primer for exon 1 of CYP82E4v2.
SEQ ID N0z34 sets forth a nucleic acid
forWard primer for exon 2 of CYP82E4v2.
SEQ ID N0z35 sets forth a nucleic acid
reverse primer for exon 2 of CYP82E4v2.
SEQ ID N0:36 sets forth a nucleic acid
forWard primer for exon 1 of CYP82E5v2.
SEQ ID N0z37 sets forth a nucleic acid
reverse primer for exon 1 of CYP82E5v2.
SEQ ID N0z38 sets forth a nucleic acid
forWard primer for exon 2 of CYP82E5v2.
SEQ ID N0z39 sets forth a nucleic acid
reverse primer for exon 2 of CYP82E5v2.
SEQ ID N0:40 sets forth a nucleic acid

forth an amino acid sequence of a

As used herein, “inhibit,” “inhibition” and “inhibiting” are
Which decreases the expression or function of a gene product

forth an amino acid sequence of a

of interest (i.e., the target gene product).

forth an amino acid sequence of a

“Inhibiting” can be in the context of a comparison betWeen
tWo plants, for example, a genetically altered plant versus a
65

forth an amino acid sequence of a

Wild-type plant. The comparison can be betWeen plants, one
of Which lacks a DNA sequence capable of reducing the
agent. Inhibition of expression or function of a target gene

US 8,124,851 B2
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position. See, FIGS. 1A-C. As used herein, a “fragment”

product also can be in the context of a comparison between

plant cells, organelles, organs, tissues orplant parts Within the

means a portion of a polynucleotide or a portion of a polypep

same plant or betWeen different plants, and includes compari
sons betWeen developmental or temporal stages Within the
same plant or plant part or betWeen plants or plant parts.
“Inhibiting” can include any relative decrement of function
or production of a gene product of interest, up to and includ
ing complete elimination of function or production of that

tide and hence protein encoded thereby.
As used herein, “plant part” means plant cells, plant pro
toplasts, plant cell tissue cultures from Which a Whole plant
can be regenerated, plant calli, plant clumps and plant cells

pollen, anthers, ovules, seeds, leaves, ?oWers, stems,

gene product. When levels of an agent are compared, such a

branches, fruit, roots, root tips and the like. Progeny, variants

comparison is preferably carried out betWeen organisms With
a similar genetic background. Preferably, a similar genetic
background is a background Where the organisms being com

and mutants of regenerated plants are also included Within the

that are intact in plants or parts of plants such as embryos,

scope of the present invention, provided that they comprise
the introduced polynucleotides of the invention. As used
herein, “tobacco plant material” means any portion of a plant
part or any combination of plant parts.

pared share 50% or greater, more preferably 75% or greater,
and, even more preferably 90% or greater sequence identity

of nuclear genetic material. A similar genetic background is a

As used herein, “operably linked” means a functional link
age betWeen tWo or more elements. For example, an operable

background Where the organisms being compared are plants,
and the plants are isogenic except for any genetic material

linkage betWeen a polynucleotide of interest and a regulatory
sequence (i.e., a promoter) is a functional link that alloWs for

originally introduced using plant transformation techniques
or a mutation generated by human intervention. Measurement
of the level or amount of an agent may be carried out by any

expression of the polynucleotide of interest. Operably linked
20

suitable method, non-limiting examples of Which include, but

elements may be contiguous or non-contiguous. When used

to refer to the fusing of tWo protein coding regions, by oper

are not limited to, comparison of mRNA transcript levels,

ably linked is intended that the coding regions are in the same

protein or peptide levels, and/or phenotype, especially the

reading frame.

conversion of nicotine to nornicotine. As used herein, mRNA

transcripts can include processed and non-processed mRNA
transcripts, and polypeptides or peptides can include
polypeptides or peptides With or Without any post-transla

As used herein, “heterologous” means a sequence that
25

tional modi?cation.
As used herein, “host cell” means a cell that comprises a

heterologous nucleic acid sequence of the invention. Though
the nucleic acid sequences of the invention, and fragments
and variants thereof, can be introduced into any cell of inter
est, of particular interest are plant cells, more particularly
cells of a Nicoliana plant species, for example, the tobacco
plant species and varieties described herein beloW.

30

originates from a foreign species, or, if from the same species,
is substantially modi?ed from its native form in composition
and/or genomic locus by deliberate human intervention. For
example, a promoter operably linked to a heterologous poly
nucleotide is from a species different from the species from
Which the polynucleotide Was derived, or, if from the same/
analogous species, one or both are substantially modi?ed

from their original form and/or genomic locus, or the pro
moter is not the native promoter for the operably linked poly
nucleotide. Furthermore, as used herein, “chimeric gene”
35

As used herein, “variant” means a substantially similar

means a coding sequence operably linked to a transcription

initiation region that is heterologous to the coding sequence.

sequence. A variant can have different function or a substan

tially similar function as a Wild-type polypeptide of interest.
For a nicotine demethylase, a substantially similar function is

at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 75%, 60%,

DETAILED DESCRIPTION OF THE INVENTION
40

Nicotine Demethylase Polynucleotides and Polypeptides,

50%, 25% or 15% of Wild-type enZyme function of convert

and Variants and Fragments Thereof

ing nicotine to nomicotine under the same conditions or in a

Compositions of the present invention include cytochrome
P450 polypeptides. Cytochrome P450 polypeptides can have

near-isogenic line. A Wild-type CYP82E5v2 is SEQ ID N012.
A Wild-type CYP82E4v2 is SEQ ID NO: 13. As used herein,

nicotine demethylase activity. Such nicotine demethylase

a “variant polynucleotide” or “variant polypeptide” means a 45 polynucleotides and polypeptides are involved in the meta

nucleic acid or amino acid sequence that is not Wild-type.
A variant can have one addition, deletion or substitution;
tWo or less additions, deletions or substitutions; three or less

additions, deletions or substitutions; four or less additions,
deletions or substitutions; or ?ve or less additions, deletions

50

bolic conversion of nicotine to nomicotine in plants, includ
ing commercial varieties of tobacco plants. Also included are
variants of such nicotine demethylases. In particular, compo
sitions of the invention include isolated polypeptides com
prising amino acid sequences as shoWn in SEQ ID NOS:2 and

5-24, isolated polynucleotides comprising the nucleic acid

or substitutions. A mutation includes additions, deletions, and
substitutions. Such deletions or additions can be at the C-ter

sequences as shoWn in SEQ ID NOS:1, 3 and 4, and the

minus, N-terminus or both the C- and N-termini. Fusion

isolated polynucleotides encoding polypeptides comprising

polypeptides or epitope-tagged polypeptides are also
included in the present invention. “Silent” nucleotide muta
tions do not change the encoded amino acid at a given posi

amino acid sequences of SEQ ID NOS:2 and 5-24. The poly
55

nucleotides of the present invention can ?nd use in inhibiting

expression of nicotine demethylase polypeptides or variants

tion. Amino acid substitutions can be conservative. A conser

thereof that are involved in the metabolic conversion of nico

vative substitution is a change in the amino acid Where the
change is to an amino acid Within the same family of amino

tine to nomicotine in plants, particularly tobacco plants.

acids as the original amino acid. The family is de?ned by the
side chain of the individual amino acids. A family of amino
acids can have basic, acidic, uncharged polar or nonpolar side

Some of the polynucleotides of the invention have mutations
60

present invention is effective in loWering nomicotine levels in

chains. See, Alberts et al., (1994) Molecular biology ofthe
cell (3rd ed., pages 56-57, Garland Publishing Inc., NeW
York, N.Y.), incorporated herein by reference as if set forth in
its entirety. A deletion, substitution or addition can be to the
amino acid of another CYP82E family member in that same

that inhibit nicotine demethylase activity of the Wild-type
nicotine demethylase. The inhibition of polypeptides of the
tobacco lines Where genetic conversion occurs in less than
30%, 50%, 70% and 90% of the population, such as ?ue

65

cured tobaccos. The inhibition of polypeptides of the present
invention is effective in loWering nomicotine levels in
tobacco populations Where genetic conversion occurs in at

US 8,124,851 B2
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least 90%, 80%, 70%, 60% and 50% of a plant population. A

otide can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb,
0.5 kb or 0.1 kb of nucleotide sequence that naturally ?ank the
polynucleotide in genomic DNA of the cell from Which the

population preferably contains greater than about 25, 50, 100,
500, 1,000, 5,000 or 25,000 plants Where, more preferably at
least about 10%, 25%, 50%, 75%, 95% or 100% ofthe plants
comprise a polypeptide of the present invention.
The present invention further provides expression cassettes
comprising all or a portion of the polynucleotides having a
amino acid sequence of SEQ ID NOS: 2 and 5-24, a comple

polynucleotide is derived. A polypeptide that is substantially
free of cellular material includes preparations having less
than about 30%, 20%, 10%, 5% or 1% (by dry Weight) of
contaminating protein. When the polypeptide of the invention
or biologically active portion thereof is recombinantly pro
duced, optimally culture medium represents less than about
30% 20%, 10%, 5% or 1% (by dry Weight) of chemical

ment or fragment thereof, or a sequence having substantial

precursors or non-protein-of-interest chemicals.

sequence identity to SEQ ID NO: 1, 3 or 4, or the polynucle
otides encoding polypeptides having an amino acid sequence
of SEQ ID NOS:2 and 5-24, or a complement or fragment
thereof, operably linked to a heterologous promoter that is
functional in a plant cell for use in expressing an inhibitory

Fragments of the disclosed polynucleotides and polypep
tides encoded thereby are also encompassed by the present
invention. Fragments of a polynucleotide may encode

nucleic acid sequence set forth in SEQ ID NO: 1, 3 or 4, and

the isolated polynucleotides encoding polypeptides having an

polypeptide fragments that retain the biological activity of the
native polypeptide and hence are involved in the metabolic
conversion of nicotine to nornicotine in a plant. Alternatively,
fragments of a polynucleotide that are useful as hybridization

RNA transcript that interferes With expression (i.e., transcrip
tion and/ or translation) of nicotine demethylase polypeptides.
In some embodiments, the expression cassettes comprise the
nucleotide sequence as shoWn in SEQ ID NO: 1, 3 or 4, a

complement or fragment thereof, or a sequence having sub
stantial sequence identity to SEQ ID NO: 1, 3 or 4, or a
complement or fragment thereof. Introduction of these
expression cassettes into a Nicoliana plant of interest; par
ticularly a tobacco plant of varieties commonly knoWn as ?ue

probes or PCR primers using methods described beloW gen
20

nucleotides include those that can be assembled Within
recombinant constructs for use in gene silencing With any
method knoWn in the art, including, but not limited to, sense
25

suppression/cosuppression, antisense suppression, double
stranded RNA (dsRNA) interference, hairpin RNA interfer
ence and intron-containing hairpin RNA interference, ampli
con-mediated interference, riboZymes and small interfering

30

Thus, fragments of a polynucleotide may range from at least
about 20 nucleotides, about 50 nucleotides, about 70 nucle

or bright varieties, Burley varieties, dark varieties and orien
tal/Turkish varieties, results in the production of tobacco
plants having reduced amounts of nornicotine and NNN. Leaf
and stem material from these transgenic plants can be used to

produce a variety of tobacco products having, reduced levels

RNA or micro RNA, as described in the art and herein beloW.

of nornicotine, and a concomitant reduction NNN.

The nicotine demethylase polynucleotides and encoded
polypeptides of the present invention include a novel cyto
chrome P450 gene, designated the CYP82E5v2 nicotine
demethylase gene, that is neWly identi?ed as having a role in
the metabolic conversion of nicotine to nornicotine in tobacco

otides, about 100 nucleotides about 150 nucleotides, about
200 nucleotides, 250 nucleotides, 300 nucleotides and up to

the full-length polynucleotide encoding the polypeptides of
35

plants. Suppression of the expression of the encoded polypep
tide in transgenic tobacco plants results in a signi?cant reduc
tion in the accumulation of nornicotine in the green leaves of

these transgenic plants. While not being bound by theory, the

40

metabolic role of these polypeptides may be a direct one, i.e.,

directly catalyZing the N-demethylation reaction, or an indi
rect one, i.e., in the form of production of a product that leads

to the up-regulation of the nicotine demethylase activity of
the leaf. Regardless of the mechanism, any means by Which
expression and/or function of the polypeptides of the present

?ed polynucleotide or polypeptide compositions of the
present invention. An “isolated” or “puri?ed” polynucleotide
or polypeptide, or biologically active portion thereof, is sub
stantially or essentially free from components that normally

fragment can be betWeen about 300 and about 450 contiguous
45

50

tion Will encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175,
200, 250, 300, 350, 400, 450 or 500 contiguous amino acids,
or up to the total number of amino acids present in a full

length nicotine demethylase polypeptide of the invention
55

found in its naturally occurring environment. Thus, an iso
lated or puri?ed polynucleotide or polypeptide is substan
tially free of other cellular material or culture medium When
60

(e.g., 517 amino acids for SEQ ID NOS:2 and 5), or Will
encode at least 15, 25, 30, 50, 75, 100, 125, 150 or up to the
total number of amino acids present in a partial-length cyto
chrome P450 polypeptide of the invention (e.g., 422 for SEQ

ID NO: 12). Preferably, the fragment comprises up to amino
acid residue 330 of the encoded polypeptide. A biologically
active portion of a nicotine demethylase polypeptide can be
prepared by isolating a portion of one of the cytochrome P450

polynucleotides of the present invention, expressing the
encodedportion of the cytochrome P450 polypeptide (e. g., by
recombinant expression in vitro), and assessing the activity of
the encoded portion of the cytochrome P450 polypeptide, i.e.,

chemical precursors or other chemicals When chemically syn
thesiZed. Optimally, an “isolated” polynucleotide is free of

sequences (optimally protein encoding sequences) 110 that
naturally ?ank the polynucleotide (i.e., sequences located at
the 5' and 3' ends of the polynucleotide) in the genomic DNA
of the organism from Which the polynucleotide is derived. For
example, in various embodiments, the isolated polynucle

nucleotides in length.
A fragment of a nicotine demethylase polynucleotide of
the present invention that encodes a biologically active por
tion of a cytochrome P450 polypeptide of the present inven

accompany or interact With the polynucleotide or protein as

produced by recombinant techniques, or substantially free of

the invention, depending upon the desired outcome. For
example, the fragments of a polynucleotide can be betWeen
100 and about 350 nucleotides, betWeen 100 and about 325
nucleotides, betWeen 100 and about 300 nucleotides, betWeen
about 125 and about 300 nucleotides, betWeen about 125 and
about 275 nucleotides in length, betWeen about 200 to about
320 contiguous nucleotides, betWeen about 200 and about
420 contiguous nucleotides in length betWeen about 250 and

about 450 contiguous nucleotides in length. Alternatively, the

invention are targeted for inhibition or site-directed mutagen

esis Within a Nicoliana plant Will be effective in reducing
nornicotine levels, and levels of NNN, Within leaves and
stems of these plants.
The invention encompasses isolated or substantially puri

erally do not encode fragment polypeptides retaining biologi
cal activity. Furthermore, fragments of the disclosed poly

65

the ability to promote conversion of nicotine to nornicotine,
using assays knoWn in the art and those provided herein
beloW.
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Polynucleotides that are fragments of a cytochrome P450
nucleotide sequence of the present invention comprise at least

10, as feW as 9, as feW as 8, as feW as 7, as feW as 6, as feW as
5, as feW as 4, as feW as 3, as feW as 2, or as feW as 1 amino acid

16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500,
550, 600, 650, 700, 800, 900, 950, 1000, 1050, 1100, 1150,
1200, 1250, 1300,1350, 1400,1450, 1500,1550, 1600,1650

residue.

or 1700 contiguous nucleic acids, or up to the number of

a nicotine demethylase polypeptide that is involved in the
metabolic conversion of nicotine to nornicotine in plants.
Such polynucleotide variants can comprise a deletion and/or

Variants of the polynucleotides of the present invention

include those naturally occurring polynucleotides that encode

nucleotides present in a full-length cytochrome P450 poly
nucleotide as disclosed herein (e.g., 1554 for SEQ ID NO:1;
or 2608 for SEQ ID NO:4). Polynucleotides that are frag

addition of one or more nucleotides at one or more sites

ments of a cytochrome P450 nucleotide sequence of the

Within the native polynucleotide disclosed herein and/or a

present invention comprise fragments from about 20 to about
1700 contiguous nucleic acids, from about 50 to about 1600

the native polynucleotide. Because of the degeneracy of the

contiguous nucleic acids, from about 75 to about 1500 con
tiguous nucleic acids, from about 100 to about 1400 nucleic
acids, from about 150 to about 1300 contiguous nucleic acids,
from about 150 to about 1200 contiguous nucleic acids, from
about 175 to about 1 100 contiguous nucleic acids, from about
200 to about 1000 contiguous nucleic acids, from about 225
to about 900 contiguous nucleic acids, from about 500 to
about 1600 contiguous nucleic acids, from about 775 to about
1700 contiguous nucleic acids, from about 1000 to about
1700 contiguous nucleic acids, or from about 300 to about
800 contiguous nucleic acids from a cytochrome P450 poly
nucleotide as disclosed herein. For example, polynucleotide
fragment can comprise a polynucleotide sequence containing
the nucleic acid sequence from the polynucleotide at about
position 700 to about position 1250 of a cytochrome P450
coding sequence, at about position 700 to about position 1250
of a cytochrome P450 genomic sequence, at about position 10
to about position 900 of a cytochrome P450 intron sequence,
or at about position 100 to about position 800 of a cytochrome

substitution of one or more nucleotides at one or more sites in

genetic code, conservative variants for polynucleotides
include those sequences that encode the amino acid sequence
of one of the cytochrome P450 polypeptides of the invention.
Naturally occurring variants such as these can be identi?ed
With the use of Well-known molecular biology techniques, as,

e.g., With polymerase chain reaction (PCR) and hybridization
20

Variant polynucleotides also include synthetically derived
polynucleotides, such as those generated, e.g., by using site
directed mutagenesis but Which still share substantial
sequence identity to the naturally occurring sequences dis
25

30

at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,
35

80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,

40

98%, 99% or more sequence identity to that particular poly
nucleotide as determined by sequence alignment programs
and parameters described elseWhere herein.
Variants of a particularpolynucleotide of the present inven
tion (also referred to as the reference polynucleotide) can also

be evaluated by comparison of the percent sequence identity
betWeen the polypeptide encoded by the reference polynucle
otide and the polypeptide encoded by a variant polynucle
45

otide. Percent sequence identity betWeen any tWo polypep
tides can be calculated using sequence alignment programs
and parameters described elseWhere herein. Where any given
pair of polynucleotides of the invention is evaluated by com

parison of the percent sequence identity shared by the tWo

conversion of nicotine to nornicotine in plants, or not. Such

polypeptides they encode, the percent sequence identity

variants may result from, e.g., genetic polymorphism or from
human manipulation as occurs With breeding and selection.

nicotine to nornicotine, including the nicotine demethylase
polypeptides set forth in SEQ ID NOS:2, 5, 7-11, 13, 16-21
and 23-24. Generally, variants of a particular polynucleotide
of the invention, e.g., the polynucleotide sequence of SEQ ID
N023 or the polynucleotide sequence encoding the amino
acid sequence set forth in SEQ ID NO2 and 5-24, Will have

of the invention can be used to target expression or function of

any naturally occurring cytochrome P450 that shares sub stan
tial sequence identity to the disclosed cytochrome P450
polypeptides. Such cytochrome P450 can possess the relevant
cytochrome P450 activity, i.e., involvement in the metabolic

closed herein, and thus can be used in the methods of the
invention to inhibit the expression or function of a nicotine

demethylase that is involved in the metabolic conversion of

P450 intron sequence.

Variants of the disclosed polynucleotides and polypeptides
encoded thereby are also encompassed by the present inven
tion. Naturally occurring variants include those variants that
share substantial sequence identity to the disclosed cyto
chrome P450 polynucleotides and polypeptides disclosed
herein. Naturally occurring variants can share substantial
functional identity to the disclosed cytochrome P450 poly
nucleotides disclosed herein. The compositions and methods

techniques as are knoWn in the art and disclosed herein.

50

betWeen the tWo encoded polypeptides is at least about 40%,

Biologically active variants of a cytochrome P450 protein of

45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,

the invention, such as variants of the polypeptide set forth in
SEQ ID NO2 and 5-24, Will have at least about 40%, 45%,

91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more
sequence identity. A variant polypeptide of the present inven

50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more

55

tion can include a polypeptide having a serine at position 458,
an asparagine at position 364 of the cytochrome P450

polypeptide, a stop codon at position 329 of the cytochrome

sequence identity to the amino acid sequence for the Wild

type protein as determined by sequence alignment programs

P450 or any combination thereof, Where the numbering cor

and parameters described elseWhere herein, and can be char
acteriZed by a functional involvement in the metabolic con
version of nicotine to nornicotine in plants or lack thereof. A
biologically active variant of a polypeptide of the invention

60

responds to SEQ ID NO:13.
Furthermore, the polynucleotides of the invention can be
used to isolate corresponding cytochrome P450 sequences
from other organisms, particularly other plants, more particu
larly other members of the Nicoliana genus. PCR, hybridiza

65

tion and other like methods can be used to identify such
sequences based on their sequence homology to the
sequences set forth herein. Sequences isolated based on their
sequence identity to the nucleotide sequences set forth herein
or to variants and fragments thereof are encompassed by the

may differ by as feW as 1-15 amino acid residues, as feW as 10,
as feW as 9, as feW as 8, as feW as 7, as feW as 6, as feW as 5,
as feW as 4, as feW as 3, as feW as 2, or as feW as 1 amino acid

residue from the Wild-type polypeptide. A biologically inac
tive variant of a protein of the invention may differ from that
polypeptide by as feW as 1-15 amino acid residues, as feW as

US 8,124,851 B2
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present invention. Such sequences include sequences that are

in 0.5>< to 1><SSC at 55 to 60° C. Exemplary high stringency
conditions include hybridization in 50% formamide, 1 M

orthologs of the disclosed sequences.
As used herein, “orthologs” means genes derived from a

NaCl, 1% SDS at 37° C. and a Wash in 0.1><SSC at 60 to 65°

common ancestral gene that are found in different species as

C. Optionally, Wash buffers may comprise about 0.1% to
about 1% SDS. Duration of hybridization is generally less
than about 24 hours, usually about 4 to about 12 hours. The

a result of speciation. Genes found in different species are

considered orthologs When their nucleotide sequences and/or
their encoded protein sequences share at least 60%, 70%,

duration of the Wash time Will be at least a length of time

suf?cient to reach equilibrium.

75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,

Preferably, stringency conditions include hybridization in

97%, 98%, 99% or greater sequence identity. Functions of
orthologs are often highly conserved among species. Thus,
isolated polynucleotides that encode for a nicotine demethy
lase polypeptide that is involved in the nicotine-to-nomico
tine metabolic conversion and Which hybridize under strin
gent conditions to the cytochrome P450 sequences disclosed

a solution containing 5><SSC, 0.5% SDS, 5><Denhardt’s, 0.45
ug/ul poly A RNA, 0.45 ug/ul calf thymus DNA and 50%
formamide at 42° C., and at least one post-hybridization Wash
in a solution comprising from about 0.01><SSC to about
1><SSC. The duration of hybridization is from about 14 to
about 16 hours.

herein, or to variants or fragments thereof, are encompassed
by the present invention. Such sequences can be used in the
methods of the present invention to inhibit expression of
nicotine demethylase polypeptides that are involved in the
metabolic conversion of nicotine to nomicotine in plants.

Using PCR, oligonucleotide primers can be designed for

Speci?city is typically the function of post-hybridization

20

use in PCR reactions to amplify corresponding DNA
sequences from cDNA or genomic DNA extracted from any

(log M)+0.41 (% GC)-0.61 (% form)-500/L; Where M is the

plant of interest. Methods for designing PCR primers and
PCR cloning are generally knoWn in the art and are disclosed

in Sambrook et al. (1989) Molecular cloning: a laboratory

25

manual (2d ed, Cold Spring Harbor Laboratory Press, Plain
vieW, N.Y.). lnnis et al., eds. (1990) PCRprotocols: a guide to

methods and applications (Academic Press, NeWYork); Innis
& Gelfand, eds. (1995) PCR strategies (Academic Press,
NeW York); and Innis & Gelfand, eds. (1999) PCR methods
manual (Academic Press, NeW York). Known methods of
PCR include, but are not limited to, methods using paired

30

sought, the Tm can be decreased 10° C. Generally, stringent
35

(Tm); moderately stringent conditions can utilize a hybridiza
tion and/ or Wash at 6, 7, 8, 9 or 10° C. loWer than the thermal
40

hybridization and Wash compositions, and desired Tm, those
45

50

tively, stringency conditions can be adjusted to alloW some

7.0 to 8.3 and the temperature is at least about 30° C. Stringent
conditions may also be achieved With the addition of desta

of ordinary skill Will understand that variations in the strin
gency of hybridization and/or Wash solutions are inherently
described. If the desired degree of mismatching results in a
Tm, of less than 45° C. (aqueous solution) or 32° C. (forma
mide solution), it is optimal to increase the SSC concentration
so that a higher temperature can be used. An extensive guide

conditions, target sequences that are 100% complementary to

mismatching in sequences so that loWer degrees of similarity
are detected (heterologous probing). Generally, a probe is less
than about 1000 nucleic acids in length, optimally less than
500 nucleic acids in length.
Typically, stringent conditions Will be those in Which the
salt concentration is less than about 1.5 M Na ion, typically
about 0.01 to 1.0 M Na ion concentration (or other salts) at pH

melting point (Tm); loW stringency conditions can utilize a
hybridization and/or Wash at 11, 12, 13, 14, 15 or 20° C. loWer

than the thermal melting point (Tm). Using the equation,

trolling the stringency of the hybridization and/or Washing
the probe can be identi?ed (homologous probing). Alterna

thermal melting point (Tm) for the speci?c sequence and its
complement at a de?ned ionic strength and pH. HoWever;
severely stringent conditions can utilize a hybridization and/
or Wash at 1, 2, 3 or 4° C. loWer than the thermal melting point

hybridization conditions” means conditions under Which a

probe Will hybridize to its target sequence to a detectably
greater degree than to other sequences (e.g., at least tWo-fold
over background). Stringent conditions are sequence-depen
dent and Will be different in different circumstances. By con

tions can be adjusted to hybridize to sequences of the desired

conditions are selected to be about 5° C. loWer than the

Hybridization techniques involve the use of all or part of a

knoWn polynucleotide as a probe that selectively hybridizes
to other corresponding polynucleotides present in a popula
tion of cloned genomic DNA fragments or cDNA fragments
(i.e., genomic or cDNA libraries) from a chosen organism.
Hybridization may be carried out under stringent condi
tions. As used herein, “stringent conditions” or “stringent

molarity of monovalent cations, % GC is the percentage of
guanosine and cytosine nucleotides in the DNA, % form is the
percentage of formamide in the hybridization solution, and L
is the length of the hybrid in base pairs. The Tm is the tem
perature (under de?ned ionic strength and pH) at Which 50%
of a complementary target sequence hybridizes to a perfectly
matched probe. Tm is reduced by about 1° C. for each 1% of
mismatching; thus, Tm, hybridization, and/ or Wash condi
identity. For example, if sequences With 290% identity are

primers, nested primers, single speci?c primers, degenerate
primers, gene-speci?c primers, vector-speci?c primers, par
tially mismatched primers and the like.

Washes, the critical factors being the ionic strength and tem
perature of the ?nal Wash solution. For DNA-DNA hybrids,
the Tm can be approximated from the equation of Meinkoth &
Wahl (1984)Anal. Biochem. 138:267-284: Tm:81.5° C.+16.6

55

to the hybridization of nucleic acids is found in Tijssen(1993)

Laboratory techniques in biochemistry and molecular biol
ogy-hybridization with nucleic acid probes, Part 1, Chapter 2
(Elsevier, NY); and Ausubel et al., eds. (1995) Current pro
tocols in molecular biology, Chapter 2 (Greene Publishing
and Wiley-lnterscience, NeWYork). See also, Sambrook et al.
(1 989) Molecular cloning: a laboratory manual (2d ed., Cold

Spring Harbor Laboratory Press, PlainvieW, N.Y.).
Hybridization probes may be genomic DNA fragments,
cDNA fragments, RNA fragments or other oligonucleotides,
60

and may be labeled With a detectable group such as 32P, or any

other delectable marker. For example, probes for hybridiza
tion can be made by labeling synthetic oligonucleotides based

bilizing agents such as formamide. Exemplary loW stringency
conditions include hybridization With a buffer solution of 30

to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl

on the cytochrome P450 polynucleotides sequences of the

sulphate) at 37° C., and a Wash in 1x to 2><SSC (20><SSC:3.0
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary
moderate stringency conditions include hybridization in 40 to
45% formamide, 1.0 M NaCl, 1% SDS at 37° C., and a Wash

present invention. Methods for preparation of probes for
hybridization and for construction of cDNA and genomic

65

libraries are generally knoWn in the art and are disclosed in

Sambrook et al., supra.
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For example, the cytochrome P430 polynucleotides dis

chul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively,
PSI-BLAST (in BLAST 2.0) can be used to perform an iter
ated search that detects distant relationships betWeen mol
ecules. See Altschul et al. (1997) supra. When utilizing

closed herein, or one or more portions thereof, may be used as

probes capable of speci?cally hybridizing to corresponding
cytochrome P450 polynucleotides and messenger RNAs. To
achieve speci?c hybridization under a variety of conditions,
such probes include sequences that are unique among cyto

BLAST, Gapped BLAST, PSI-BLAST, the default param
eters of the respective programs (e.g., BLASTN for nucle
otide sequences, BLASTX for proteins) can be used (See

chrome P450 polynucleotide sequences or unique to one of

the cytochrome P450 polynucleotide sequences, including

WWW.ncbi.nlna.nih.gov). Alignment may also be performed

upstream regions 5' to the coding sequence and doWnstream

manually by inspection.

regions 3' to the coding sequence and an intron region, and are

The sequence identity/similarity values provided herein

optimally at least about 10 contiguous nucleotides in length,

Were calculated using the BLASTX (Altschul et al. (1997)
supra), Clustal W (Higgins et al. (1994) Nucleic Acids Res.
22:4673-4680), and GAP (University of Wisconsin Genetic

more optimally at least about 20 contiguous nucleic acids in
length, more optimally at least about 50 contiguous nucleic
acids in length, more optimally at least about 75 contiguous
nucleic acids in length, and more optimally at least about 100

Computing Group softWare package) algorithms using
default parameters. The present invention also encompasses
the use of any equivalent program thereof for the analysis and

contiguous nucleic acids in length. Such probes may be used

to amplify corresponding cytochrome P450 polynucleotides.

comparison of nucleic acid and protein sequences. By
“equivalent program” is intended any sequence comparison

This technique may be used to isolate additional coding
sequences or mutations from a desired plant or as a diagnostic

assay to determine the presence of coding sequences in a

20

plant. Hybridization techniques include hybridization screen
ing of plated DNA libraries (either plaques or colonies; see,

compared to the corresponding alignment generated by
BLASTX. Clustal W, or GAP.

e.g., Sambrook et al., supra.

For purposes of the foregoing discussion of variant nucle

As used herein, With respect to the sequence relationships
betWeen tWo or more polynucleotides or polypeptides, the
term “reference sequence” means a de?ned sequence used as

a basis for sequence comparison. A reference sequence may
be a subset or the entirety of a speci?ed sequence; for
example, as a segment of a full-length cDNA or gene
sequence, or the complete cDNA or gene sequence.
As used herein, “comparison WindoW” means a contiguous

25

invention, “sequence identity” or “identity” in the context of
ence to the residues in the tWo sequences that are the same

When aligned for maximum correspondence over a speci?ed
30

amino acid substitutions, Where amino acid residues are sub
stituted for other amino acid residues With similar chemical
35

properties (e.g., charge or hydrophobicity) and therefore do

40

not change the functional properties of the molecule. When
sequences differ in conservative substitutions, the percent
sequence identity may be adjusted upWards to correct for the
conservative nature of the substitution. Sequences that differ
by such conservative substitutions are said to have “sequence

Generally, a comparison WindoW is at least 20 contiguous
nucleic acids in length, and optionally can be 30, 40, 50 or 100
contiguous nucleic acids or longer. Those of skill in the art
sequence a gap penalty is typically introduced and is sub
tracted from the number of matches.
Methods of alignment of sequences for comparison are
Well knoWn in the art. Thus, the determination of percent

similarity” or “similarity.” Means for malting this adjustment
are Well knoWn to those of skill in the art. Typically this
involves scoring a conservative substitution as a partial rather
45

Proc. Natl. Acad. Sci. USA 872264, modi?ed as in Karlin &
Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.

than a full mismatch, thereby increasing the percentage
sequence identity. Thus, for example, Where an identical
amino acid is given a score of 1 and a non-conservative
substitution is given a score of zero, a conservative substitu
tion is given a score betWeen zero and 1. The scoring of
conservative substitutions is calculated, e. g., as implemented

sequence identity betWeen any tWo sequences can be accom

plished using a mathematical algorithm. Non-limiting
examples of such mathematical algorithms are the algorithm
of Myers & Miller (1988) CABIOS 4: 11-17; the local align
ment algorithm ofSmith et al. (1981)Adv. Appl. Math. 2:482;
the global alignment algorithm of Needleman & Wunsch
(1970) J. Mol. Biol. 48:443-453; the search-for-local align
ment method of Pearson & Lipman (1988) Proc. Natl. Acad.
Sci. 85 :2444-2448; the algorithm of Karlin &Altschul (1990)

comparison WindoW. When percentage of sequence identity
is used in reference to proteins it is recognized that residue
positions Which are not identical often differ by conservative

deletions) for optimal alignment of the tWo polynucleotides.

understand that to avoid a high similarity to a reference
sequence due to inclusion of gaps in the polynucleotide

otide and polypeptide sequences encompassed by the present
tWo polynucleotides or polypeptide sequences makes refer

and speci?ed segment of a polynucleotide sequence, Where
the polynucleotide sequence in the comparison WindoW may
comprise additions or deletions (i.e., gaps) compared to the
reference sequence (Which does not comprise additions or

program that, for any tWo sequences in question, generates an
alignment having identical nucleotide or amino acid residue
matches and an identical percent sequence identity When

50

in the program PC/GENE (lntelligenetics; Mountain VieW,

Calif.).
As used herein, “percentage of sequence identity” means

the value determined by comparing tWo optimally aligned
sequences over a comparison WindoW, Where the portion of
55

the polynucleotide sequence in the comparison WindoW may
comprise additions or deletions (i.e., gaps) as compared to the

The BLAST programs ofAltschul et al. (1 990) J. Mol. Biol.

reference sequence (Which does not comprise additions or

215:403 are based on the algorithm of Karlin & Altschul

deletions) for optimal alignment of the tWo sequences. The
percentage is calculated by determining the number of posi

(1990) supra. BLAST nucleotide searches can be performed
With the BLASTN program, score:100, Wordlength:12, to

60

obtain nucleotide sequences homologous to a nucleotide

sequence encoding a protein of the invention. BLAST protein
searches can be performed With the BLASTX program,
score:50. Wordlength:3, to obtain amino acid sequences
homologous to a protein or polypeptide of the invention. To

obtain gapped alignments for comparison purposes, Gapped
BLAST (in BLAST 2.0) can be utilized as described in Alts

65

tions at Which the identical nucleic acid base or amino acid
residue occurs in both sequences to yield the number of

matched positions, dividing the number of matched positions
by the total number of positions in the WindoW of comparison,
and multiplying the result by 100 to yield the percentage of
sequence identity.

Thus, cytochrome P450 polynucleotide and polypeptide
sequences can be identi?ed using the sequences provided

US 8,124,851 B2
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herein. Such methods include obtaining a polynucleotide or

chrome P450 intron. For a cytochrome P450 intron fragment,
the entire sequence of a cytochrome P450 intron can be SEQ

polypeptide sequence at least 80%, 85%, 90%, 95%, 98% or
99% sequence identity With the polynucleotide sequence of

ID NO13.

Furthermore, a fragment of a cytochrome P450 polynucle

SEQ ID NO: 1, 3 or 4 or a complement or fragment thereof, or
a polypeptide sequence of SEQ ID NO12 or 5-24. A preferred

otide or polypeptide can contain contiguous nucleotides from

embodiment includes a polypeptide corresponding to SEQ ID

about 1, 2, 5, 10, 20, 30, 40, 50, 60,70, 80, or 90% ofthe entire

NO113 that has a serine at position 458 or an asparagine at

gene. Alternatively stated, a fragment of a cytochrome P450

position 364 of the cytochrome P450 polypeptide, or a stop
codon at position 329 of the cytochrome P450, or a combi

polynucleotide or polypeptide can be betWeen about

5%-about 80%, betWeen about 10%-about 70%, betWeen
about 10%-about 60%, betWeen about 10%-about 50%,
betWeen about 25%-about 60%, betWeen about 25%-about
50%, betWeen about 40%-about 60%, betWeen about 40%
about 80%, betWeen about 50%-about 90% of the length of an
entire cytochrome P450.
Expression cassettes of the present invention include those

nation thereof, Where the numbering corresponds to SEQ ID
NO: 13.

Expression Cassettes for Use in the Methods of Invention
Compositions of the present invention further include

expression cassettes comprising inhibitory sequences
capable of inhibiting expression or function of a nicotine

that encompass additional domains that modulate the level of

demethylase polypeptide involved in the conversion of nico

expression, the developmental timing of expression, or tissue

tine to nomicotine in a Nicotiana plant or plant part thereof,
Where the inhibitory sequences are operably linked to a pro
moter that is functional in a plant cell. In this manner, expres
sion cassettes comprising all or part of the sequence set forth
in SEQ ID NO11, 3 or 4 or encoding SEQ ID NO12 or 5-24, a
complement or fragment thereof, or sequences sharing sub
stantial sequence identity to such sequences, or a complement
or fragment thereof, operably linked to a promoter that is

type that expression occurs in (e.g., AU Patent No. AU-A
77751/94 and US. Pat. Nos. 5,466,785 and 5,635,618). Pro
20

inducible, constitutive, pathogen- or Wound-induced, envi
ronmentally- or developmentally-regulated, cell- or tissue

preferred promoter, or other promoters for expression in
25

functional in a plant cell are constructed for use in the gene

silencing methods of the present invention described herein
beloW. Such sequences are referred to herein as “inhibitory

sequences” or “inhibitory polynucleotide sequences,” as they
are capable of being expressed as an RNA molecule that

30

inhibits expression (i.e., transcription and/or translation) of

Chemical-inducible promoters can be used to inhibit the
expression of a cytochrome P450 that is involved in the meta
bolic conversion of nicotine to nomicotine in a plant through
the application of an exogenous chemical regulator. Chemi
cal-inducible promoters are knoWn in the art and include, but
are not limited to, the tobacco PR-la promoter, Which is

ers of interest include steroid-responsive promoters (see, e. g.,

polypeptide set forth in SEQ ID NO12 or 5-24 and variants

the glucocorticoid-inducible promoter (Schena et al. (1991)
35

Proc. Natl. Acad. Sci. USA 88: 10421-10425; and McNellis et

al. (1998) Plant J. 14(2):247-257) and tetracycline-inducible

polypeptides. Such variants may or may not be involved in the
metabolic conversion of nicotine to nornicotine in a plant.

Such sequences also include fragment sequences of the target
cytochrome P450 polynucleotide or polypeptide. For

plants.

activated by salicylic acid. Other chemical-inducible promot

the target cytochrome P450 polypeptide, for example, the
thereof, Where the variant polypeptides have substantial
sequence identity to these disclosed cytochrome P450

moters can be selected based on the desired outcome. The

nucleic acids of the present invention can be combined With

40

example, a fragment sequence can include any portion of the

cytochrome P450 sequence, including coding and non-cod
ing sequence (e.g., 5' UTR, intron, and 3' UTR sequences),

promoters (see, e.g., GatZ et al. (1991) Mol. Gen. Genet.
2271229-237; and US. Pat. Nos. 5,814,618 and 5,789,156),
each of Which is incorporated herein by reference as if set
forth in its entirety.
Constitutive promoters include, e.g., the core promoter of
the Rsyn7 promoter and outer constitutive promoters dis
closed in US. Pat. No. 6,072,050; the core CaMV 35S pro

and can include fragments betWeen 100 and about 350

nucleic acids, betWeen about 125 and about 300 nucleic acids,
orbetWeen about 125 and about 275 nucleic acids. Preferably,
a fragment of nicotine demethylase can be betWeen about 20
and about 420, about 30 and about 420, betWeen about 40 and
about 320, betWeen about 50 and about 200, betWeen about 50
and about 400, betWeen about 50 and about 420, betWeen
about 60 and about 320, about 70 and about 220, betWeen
about 100 and about 200, betWeen about 100 and about 320,
betWeen about 150 and about 200, betWeen about 150 and
about 220, betWeen about 150 and about 400, betWeen about

45
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moter (Odell et al. (1985) Nature 3131810-812); ubiquitin
(Christensen et al. (1989) Plant Mol. Biol. 121619-632; and
Christensen et al. (1992) Plant Mol. Biol. 181675-689);
pEMU (Last et al. (1991) Theo}: Appl. Genet. 811581-588);
MAS (Velten et al. (1984) EMBO J 312723-2730); ALS
promoter (US. Pat. No. 5,659,026), and the like. Other con
stitutive promoters include, e.g., those disclosed in US. Pat.

Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785;
5,399,680; 5,268,463; 5,608,142 and 6,177,611.
Tissue-preferred promoters can be utiliZed to target expres
sion of an inhibitory polynucleotide sequence of the present
invention Within a particular plant tissue. Tissue-preferred
promoters include those disclosed inYamamoto et al. (1997)
Plant .1. 12(2)1255-265; KaWamata et al. (1997) Plant Cell
Physiol. 38(7)1792-803; Hansen et al. (1997) Mol. Gen.
Genet. 254(3)1337-343; Russell et al. (1997) Transgenic Res.

200 and about 300, or betWeen about 300 and about 400

55

contiguous nucleic acids. Alternatively, a fragment of a cyto
chrome P450 can be about 100, about 150, about 200, about
220, about 250, about 300, about 320, or about 350 contigu
ous nucleic acids in length. Alternatively yet, a cytochrome
P450 fragment can be reduced in length by about 20, about

60

40, about 60, about 80, about 100, about 120, about 140, about
160, about 180, about 200, about 220, about 240, about 260,
about 280, about 290, about 300, about 320, about 340, about
360, about 380, about 400 contiguous nucleic acids compared
to the full-length. For all of these cytochrome P450 frag

6(2)1157-168; Rinehart et al. (1996) Plant Physiol. 112(3):
1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):
525-535; Canevascini et al. (1996) Plant Physiol. 112(2):
513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):
773-778; Lam (1994) Results Probl. Cell Di?‘er. 201181-196;

65

OroZco et al. (1993) Plant Mol Biol. 23(6)11129-1138; Mat
suoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20)19586
9590; and Guevara-Garcia et al. (1993) Plant.]. 4(3)1495-505.

ments, the truncation or deletion can start at the 5' end, start at
the 3' end, or be internal to a cytochrome P450 or a cyto
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Of particular interest herein are leaf preferred promoters

ing to the invention is less than 95%, less than 90%, less than
80%, less than 70%, less than 60%, less than 50%, less than
40%, less than 30%, less than 20%, less than 10%, or less than
5% of the protein level of the same cytochrome P450

that provide for expression predominately in leaf tissues. See,
e.g., Yamamoto et al. (1997)PlantJ. 12(2):255-265; KWon et

al. (1994) Plant Physiol. 105:357-67;Yamamoto et al. (1994)
Plant Cell Physiol. 35(5):773-778; Gotor et al. (1993) Plant
J. 3:509-18; OroZco et al. (1993)PlantMol. Biol. 23(6):1 129
1138; BasZcZynski et al. (1988) Nucl. Acid Res. 16:4732;
Mitra et al. (1994) Plant Molecular Biology 26:35-93;
Kayaya et al. (1995) Molecular and General Genetics 248:

polypeptide in a plant that is not a mutant or that has not been

genetically modi?ed to inhibit the expression of that cyto
chrome P450 polypeptide and Which has been cultured and
harvested using the same protocols. The expression level of

the cytochrome P450 polypeptide may be measured directly,
for example, by assaying for the level of the cytochrome P450
transcript or cytochrome P450 polypeptide expressed in the
Nicotiana plant or plant part, or indirectly, e.g., by measuring

668-674; and Matsuoka et al. (1993) Proc. Natl. Acad. Sci.

USA 90(20):9586-9590. Senecence-regulated et al. (1998)
Plant Physiol. 116:329-335); SAG 13 (Gan and Amasino

(1997) Plant Physiol. 113:313-319; SAG 15 (Gan (1995)

the conversion of nicotine to nomicotine in the Nicotiana

“Molecular Characterization and Genetic Manipulation of

plant or plant part. Methods for monitoring expression level

Plant Senescence,” Ph.D. Thesis, University of Wisconsin,

of a polypeptide are knoWn in the art, and include, but are not

Madison); SEN1 (Oh et al. (1996) Plant Mol. Biol. 30:739
754; promoter of a senescence-speci?c gene for expression of
IPT (Gan and Amasino 91995) Science 270: 1 986-1988); and
the like (see, e.g., Or et al. (1999) Plant Cell 11: 1073-1080;
and McCabe et al. (2001) Plant Physiol. 127:505-516).

limited to, Northern blot analysis and RNA differentiation
assays. Methods for determining the activity of a targeted
cytochrome P450 polypeptide in converting nicotine to nor
nicotine are knoWn in the art and described elseWhere herein
20

leader sequences that can act to enhance translation. Transla
tion leaders are knoWn in the art and include, but are not

limited to, picornavirus leaders, e.g., EMCV leader (En
cephalomyocarditis 5' noncoding region; Elroy-Stein et al.
(1989) Proc. Natl. Acid. Sci. USA 86:6126-6130); potyvirus

In some instances, the activity of one or more cytochrome

25

leaders, e.g., TEV leader (Tobacco Etch Virus; Gallie et al.

(1995) Gene 165(2):233-238), MDMV leader (MaiZe Dwarf
Mosaic Virus; I/irology 154:9-20), and human immunoglo
bulin heavy-chain binding protein (BiP; Macej ak et al. (1991)

sexual crossing, retransformation, co-transformation and the
30

use of linked transgenes. A chimeric transgene With linked
partial gene sequences can be used to coordinately suppress
numerous plant endogenous genes. Constructs modeled on
viral polyproteins can be used to simultaneously introduce
multiple coding genes into plant cells. For a revieW, see Hal

35

pin et al., Plant Mol. Biol. 47:295-310 (2001). A plant having
a mutation in CYP82E4v2 that inhibits the nicotine demethy
lase activity in senescent leaves can be crossed With a plant
having a mutation in CYP83E5v2 that inhibits nicotine dem

Physiol. 84:965-968. Other methods knoWn to enhance trans
lation also can be utiliZed.

Methods for Inhibiting Expression or Function of a Nicotine

P450 polypeptides is reduced or eliminated by transforming a
plant or plant part With an expression cassette comprising a
polynucleotide encoding a polypeptide that inhibits the activ
ity of one or more cytochrome P450 polypeptides of the
present invention. A number of approaches have been used to
combine transgenes or mutations in one plantiincluding

Nature 353:90-94); untranslated leader from the coat protein
mRNA of alfalfa mosaic virus (AMV RNA 4; Jobling et al.
(1987) Nature 325:622-625); tobacco mosaic virus leader

(TMV; Gallie et al. (1989) in Molecular biology ofRNA, ed.
Cech (Liss, NeW York), pp. 237-256); and maiZe chlorotic
mottle virus leader (MCMV; Lommel et al. (1991) I/irology
81 :382-385). See also, Della-Cioppa et al. (1987) Plant

beloW, and include, but are not limited to, alkaloid analysis

using gas chromatography.

Expression cassettes of the present invention can include 5'

40

ethylase in green leaves to produce a plant With conversion
levels loWer than about 0.2%, 0.3%, 0.4%, 0.5%, 0.6% or

Demethylase

0.7%. Alternatively, a plant having one or more mutations in

Methods of reducing the concentration, content and/or
activity of a cytochrome P450 polypeptide of the present
invention in a Nicotiana plant or plant part, particularly the
leaf tissue, are provided. Many methods may be used, alone or

CYP82E4v2 atposition 458, 364, 38, 201, 169, 459, 296, 427,
329, 376 or 171 can be crossed With a plant having one or
45

in combination, to reduce or eliminate the activity of a cyto
chrome P450 polypeptide of the present invention, more par

tively still, a plant having one or more mutations in
CYP82E4v2 at position 458, 364 or 329 can be crossed With

ticularly, the CYP82E5v2 nicotine demethylase. In addition,
combinations of methods may be employed to reduce or
eliminate the activity of tWo or more different cytochrome

more mutations in CYP83E5v2 at position 235, 449, 174,
410, 224, 72 or 143 to produce a plant With conversion levels
loWer than 0.2%, 0.3%, 0.4%, 0.5%, 0.6% or 0.7%. Altema
a plant having one or more mutations in CYP83E5v2 at

the

position 235,449, 174, 410, 224, 72, or 143 to produce a plant
With conversion levels loWer than 0.2%, 0.3%, 0.4%, 0.5%,
0.6%, or 0.7%. A particularly preferred conversion level of

CYP82E5v2 is a polypeptide With at least one amino acid

nicotine to nomicotine can be betWeen 0.05%-0.4%, between

50

P450 polypeptides, more particularly the CYP82E5v2 and

CYP82E4v2

nicotine

demethylases.

Preferably,

mutation in SEQ ID NO:2 that negatively affects conversion
in green leaves and the CYP82E4v2 has the sequence set forth
in SEQ ID NO:13 With at least one amino acid mutation that

01-06%, betWeen 0.1%-0.3%, betWeen 0.1%-0.5%,
55

negatively affects conversion in senescent leaves.
In accordance With the present invention, the expression of
a cytochrome P450 polypeptide of the present invention is

inhibited if the protein level of the cytochrome P450 polypep

tion that results in a truncation of the CYP83E4v2 or

CYP83E5v2 polypeptide before a conserved heme-binding
motif Will inhibit the enzyme and can be used in a cross
60

tide is statistically loWer than the protein level of the same
cytochrome P450 polypeptide in a plant that has not been
genetically modi?ed or mutageniZed to inhibit the expression

particular embodiments of the invention, the protein level of
the cytochrome P450 polypeptide in a modi?ed plant accord

described above. The domains of cytochrome P450 proteins
are knoWn in the art. See, e.g., Xu et al. (2007) Physiologia

Plantarum 129:307-319, incorporated herein by reference as
if set forth in its entirety. By crossing plants having a non

of that cytochrome P450 polypeptide, and Where these plants
have been cultured and harvested using the same protocols. In

betWeen 0.1%-0.4%, betWeen 0.1%-0.7%, or betWeen 0.1%
1 .0%. Any mutation of a polynucleotide of the present inven
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functional or inhibited CYP82E4v2 gene, a nonfunctional or
inhibited CYP82E5v2 gene, or nonfunctional or inhibited
CYP82E4v2 and CYP82E5v2 genes, nornicotine levels can

be reduced in a tobacco plant.
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The activity of a nicotine demethylase polypeptide in con
verting nicotine to nornicotine in a Nicoliana plant or plant
part is inhibited according to the present invention if this

formed tobacco plant has a conversion rate loWer than the rate

observed in commercial non-converter tobacco plants.
The level and/ or activity of the polypeptide may be modu
lated by employing a polynucleotide that is not capable of
directing, in a transformed plant, the expression of a protein
or an RNA. For example, the polynucleotides of the invention
may be used to design polynucleotide constructs that can be
employed in methods for altering or mutating a genomic
nucleotide sequence in an organism. Such polynucleotide

conversion activity is statistically loWer than conversion
activity of the same cytochrome P450 polypeptide in a Nic
oliana plant or plant part that has not been genetically modi
?ed to inhibit the conversion activity of that cytochrome P450
polypeptide and that has been cultured and harvested using
the same protocols. In particular embodiments, activity of a
cytochrome P450 polypeptide in converting nicotine to nor
nicotine in a modi?ed Nicoliana plant or plant part according
to the invention is inhibited if the activity is less than 95%,
less than 90%, less than 80% less than 70%, less than 60%,
less than 50%, less than 40%, less than 30%, less than 20%
less than 10%, less than 5%, less than 2% or less than 1% of
the conversion activity of the same cytochrome P450
polypeptide in a Nicoliana plant that that has not been geneti
cally modi?ed to inhibit the expression of that nicotine dem
ethylase polypeptide and that has been cultured and harvested
using the same protocols. The activity of a nicotine demethy
lase polypeptide in converting nicotine to nomicotine in a
Nicoliana plant or plant part is eliminated according to the
invention When it is not detectable by the assay methods

constructs include, but are not limited to, RNAzDNA vectors,

RNAzDNA mutational vectors, RNAzDNA repair vectors,

mixed-duplex oligonucleotides, self-complementary RNA:
DNA oligonucleotides and recombinogenic oligonucleo
bases. Such nucleotide constructs and methods of use are

knoWn in the art. See, US. Pat. Nos. 5,565,350; 5,731,181;

5,756,325; 5,760,012; 5,795,972 and 5,871,984; each of
Which is incorporated herein by reference as if set forth in its

entirety. See also, International Patent Application Publica
20

USA 96:8774-8778; each of Which is incorporated herein by
reference as if set forth in its entirety.
The methods of the present invention do not depend on the

knoWn in the art or described herein. Methods of determining

the activity of a cytochrome P450 polypeptide in converting

25

nicotine to nomicotine in a Nicoliana using gas chromatog
raphy are disclosed in the examples beloW.

or plant part thereof is altered as a result of the introduction of

30

example, the inhibitory polynucleotide, or any part thereof,

35

may incorporate into the genome of the plant. Alterations to
the genome include, but are not limited to, additions, dele
tions and substitutions of nucleotides into the genome. While
the methods of the present invention do not depend on addi
tions, deletions and substitutions of any particular number of

Subsequently, a Nicoliana plant orplant part having the intro
duced inhibiting polynucleotide of the present invention is
selected using methods knoWn to those of skill in the art

including, but not limited to, Southern blot analysis, DNA

sequencing, PCR analysis or phenotypic analysis. A poly

incorporation of the entire nicotine demethylase inhibitory
polynucleotide into the genome, only that the Nicoliana plant
this inhibitory polynucleotide into a cell. As such, the genome
may be altered folloWing the introduction of the nicotine
demethylase inhibitory polynucleotide into a cell. For

In speci?c embodiments, a cytochrome P450 inhibitory
polynucleotide or nicotine demethylase mutation described
herein is introduced into a Nicoliana plant or plant part.

tion Nos. WO 98/149350, WO 99/107865 and WO
99/125921; and Beetham et al. (1999) Proc. Natl. Acad. Sci.

nucleotide or polypeptide sequence of the present invention

nucleotides, it is recogniZed that such additions, deletions

includes

and/or substitutions comprise at least one nucleotide.
Further, one can reduce the level and/ or activity of a nico

full-length

polynucleotide

or

polypeptide

sequences, truncated polynucleotide or polypeptide
sequences, fragments of polynucleotide or polypeptide
sequences, variants of polynucleotide or polypeptide

40

tine demethylase sequence by eliciting the effects of the
sequence only during certain developmental stages and to

sequences, sense-oriented nucleotide sequences, antisense

sWitch the effect off in other stages Where expression is no

oriented nucleotide sequences, the complement of a sense- or

longer desirable. Control of nicotine demethylase expression

antisense-oriented nucleotide sequence, inverted regions of
nucleotide sequences, hairpins of nucleotide sequences,
double-stranded nucleotide sequences, single-stranded
nucleotide sequences, combinations thereof, and the like. A
plant or plant part altered or modi?ed by the foregoing is

can be obtained via the use of inducible or tissue-preferred

promoters. Alternatively, the gene could be inverted or
45

expression of the cytochrome P450 sequence.
According to the present invention, changes in levels,
ratios, activity or distribution of cytochrome P450 polypep

groWn under plant-forming conditions for a time su?icient to

modulate the concentration and/or activity of polypeptides of
the present invention in the plant. Plant forming conditions

50

tides of the present invention, or changes in Nicoliana plant or

plant part phenotype, particularly reduced accumulation of

are Well knoWn in the art and discussed brie?y elseWhere
herein.
A transformed tobacco plant containing a nicotine dem

ethylase inhibitory polynucleotide sequence described herein
has a reduced level of conversion of nicotine to nornicotine. In

55

particular embodiments, conversion of nicotine to nomico
tine in a tranformed tobacco plant or plant part according to
the invention is less than 95%, less than 90%, less than 80%
less than 70%, less than 60%, less than 50%, less than 40%,
less than 30%, less than 20%, less than 10%, less than 5%,

60

less than 2% or less than 1% of the conversion in a tobacco

nornicotine and its carcinogenic metabolite, NNN, can be
measured by comparing a subject plant or plant part to a
control plant or plant part, Where the subject plant or plant part
and the control plant or plant part have been cultured and/or
harvested using the same protocols. As used herein, a subject
plant or plant part is one in Which genetic alteration, such as
transformation, has been affected as to the nicotine demethy
lase polypeptide of interest, or is a Nicoliana plant or plant
part that is descended from a Nicoliana plant or plant part so
altered and Which comprises the alteration. A control plant or

plant part provides a reference point for measuring changes in
phenotype of the subject plant or plant part. The measurement

plant that that has not been genetically modi?ed to inhibit the

expression of that nicotine demethylase polypeptide and With
has been cultured and harvested using the same protocols. In
some instances, the transformed tobacco plant is a converter

deleted using site-speci?c recombinases, transposons or
recombination systems, Which Would also turn on or off

of changes in phenotype can be measured at any time in a
65

plant or plant part, including during plant development,

tobacco plant. Alternatively, the transformed tobacco plant is

senescence, or after curing. In other embodiments, the mea

a nonconverter tobacco plant. Alternatively still, the trans

surement of changes in phenotype can be measured in plants
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grown under any conditions, including from plants grown in

interference, amplicon-mediated interference, riboZymes,

growth chamber, greenhouse, or in a ?eld. In one embodi

and small interfering RNA or micro RNA.
For cosuppression, an expression cassette is designed to

ment, changes in phenotype can be measured by determining
the nicotine to nornicotine conversion rate. In a preferred

express an RNA molecule corresponding to all or part of a

embodiment, conversion can be measured by dividing the
percentage of nornicotine (as a percentage of the total tissue
weight) by the sum of the percentage nicotine and nornicotine

messenger RNA encoding a cytochrome P450 polypeptide of
interest (for example, a cytochrome P450 polypeptide com
prising the sequence set forth in SEQ ID NO:2 or 5-24 or a

(as percentages of the total tissue weight) and multiplying by

sequence having substantial sequence identity to SEQ ID

100.

NO:2 or 5-24) in the “sense” orientation. Over-expression of
the RNA molecule can result in reduced expression of the
native gene. Multiple plant lines transformed with the cosup
pression expression cassette are then screened to identify
those that show the greatest inhibition of nicotine demethy

According to the present invention, a control plant or plant
part may comprise a wild-type Nicoliana plant or plant part,
i.e., of the same genotype as the starting material for the

genetic alteration that resulted in the subject plant or plant
part. A control plant or plant part may also comprise a Nic

lase polypeptide expression.

oliana plant or plant part of the same genotype as the starting
material but that has been transformed with a null construct
(i.e., with a construct that has no known effect on the trait of
interest, such as a construct comprising a selectable marker

gene). Alternatively, a control plant or plan part may comprise
a Nicoliana plant or plant part that is a non-transformed
segregant among progeny of a subject plant or plant part, or a

Nicoliana plant or plant part genetically identical to the sub
ject plant or plant part but that is not exposed to conditions or
stimuli that would induce suppression of the nicotine dem
ethylase gene of interest. Finally, a control plant or plant part

20

polynucleotide comprises all or part of the coding region for
a cytochrome P450 polypeptide of the present invention, the
25

may comprise the subject plant or plant part itself under
conditions in which the nicotine demethylase inhibitory
sequence is not expressed. In all such cases, the subject plant
or plant part and the control plant or plant part are cultured
and harvested using the same protocols.
As described elsewhere herein, methods are provided to
reduce or eliminate the activity and/or concentration of a

The polynucleotide used for cosuppression may corre
spond to all or part of the sequence encoding a cytochrome
P450 polypeptide or the present invention, all or part of the 5'
and/or 3' untranslated region of a cytochrome P450 polypep
tide transcript, or all or part of both the coding sequence and
the untranslated regions of a transcript encoding a cyto
chrome P450 polypeptide. In some embodiments where the

expression cassette can be designed to eliminate the start
codon of the polynucleotide so that no polypeptide product
will be transcribed.

Cosuppression may be used to inhibit the expression of

plant genes to produce plants having undetectable levels for
30

the polypeptides encoded by these genes or may also be used
to inhibit the expression of multiple proteins in the same plant
(e.g., Broin et al. (2002) Plant Cell 14:1417-1432; and US.

Pat. No. 5,942,657). Methods for using cosuppression to

nicotine demethylase polypeptide of the present invention by

inhibit the expression of endogenous genes in plants are

introducing into a Nicoliana plant or plant part a nicotine

described in Flavell et al. (1994) Proc Natl. Acad. Sci. USA

demethylase inhibitory polynucleotide sequence than is

35

91:3490-3496; Jorgensen et al. (1996) Plant Mol. Biol.

capable of inhibiting expression or function of a nicotine

31:957-973; Johansen and Carrington (2001) Plant Physiol.

demethylase polypeptide that is involved in the metabolic

rectly, by encoding a polypeptide that inhibits the transcrip

126:930-938; Brain et al. (2002) Plant Cell 14:1417-1432;
Stoutjesdijk et al. (2002) PlanZPhysiol. 129: 1723-1731 ;Yu et
al. (2003) Phylochemislry 631753-763; and US. Pat. Nos.
5,034,323; 5,283,184 and 5,942,657; each ofwhich is incor
porated herein by reference as if set forth in its entirety. The
ef?ciency of cosuppression may be increased by including a
poly-dT region in the expression cassette at a position 3' to the
sense sequence and 5' of the polyadenylation signal. See, US
Patent Application Publication No. 2002/0048814, incorpo
rated herein by reference as if set forth in its entirety. Typi

tion or translation of a nicotine demethylase polypeptide gene

cally, such a nucleotide sequence has substantial sequence

encoding a nicotine demethylase polypeptide. Methods for
inhibiting or eliminating the expression of a gene product in

identity to the sequence of the transcript of the endogenous
gene, preferably greater than about 65% sequence identity,
more preferably greater than about 95% sequence identity,
most preferably greater than about 99% sequence identity
(e.g., US. Pat. Nos. 5,283,184 and 5,034,323; incorporated

conversion of nicotine to nornicotine. In some instances, the

inhibitory sequence can be introduced by transformation of
the plant or plant part such as a plant cell with an expression
cassette that expresses a polynucleotide that inhibits the

40

expression of the nicotine demethylase polypeptide. The
polynucleotide may inhibit the expression of a nicotine dem

ethylase polypeptide directly, by preventing translation of the
nicotine demethylase polypeptide messenger RNA, or indi

a plant are well known in the art, and any such method may be

45
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used in the present invention to inhibit the expression of

nicotine demethylase polypeptides.

herein by reference as if set forth in its entirety).

In other embodiments, the activity of a nicotine demethy
lase polypeptide of the present invention may be reduced or

eliminated by disrupting the gene encoding the nicotine dem
ethylase polypeptide. The invention encompasses
mutageniZed plants that carry mutations in cytochrome P450

55

sion cassette is designed to express an RNA molecule
complementary to all or part of a messenger RNA encoding

genes, where the mutations reduce expression of the nicotine
demethylase gene or inhibit the activity of an encoded nico

tine demethylase polypeptide of the present invention.

the cytochrome P450 polypeptide. Over-expression of the
60

pression, double-stranded RNA (dsRNA) interference, hair
pin RNA interference and intron-containing hairpin RNA

antisense RNA molecule can result in reduced expression of

the native gene. Accordingly, multiple plant lines transformed

To obtain the desired plants, a Nicoliana plant or plant part
can be transformed with an expression cassette that is capable
of expressing a polynucleotide that inhibits the expression of
a nicotine demethylase sequence. Such methods may include
the use of sense suppression/cosuppression, antisense sup

Inhibition of the expression of the cytochrome P450
polypeptide of the present invention also can be obtained by
antisense suppression. For antisense suppression, the expres

with the antisense suppression expression cassette are
screened to identify those that show the greatest inhibition of

nicotine demethylase polypeptide expression.
65

The polynucleotide for use in antisense suppression may
correspond to all or part of the complement of the sequence
encoding the cytochrome P450 polypeptide, all or part of the
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complement of the 5' and/or 3' untranslated region of the
cytochrome P450 polypeptide transcript, or all or part of the
complement of both the coding sequence and the untranslated
regions of a transcript encoding the cytochrome P450
polypeptide. In addition, the antisense polynucleotide may be

nucleotide causes the degradation of the endogenous messen

ger RNA, resulting in reduced expression of the cytochrome
P450 polypeptide. This method is described, for example, in
Us. Pat. No. 4,987,071, incorporated herein by reference as
if set forth in its entirety.
In other instances, inhibition of the expression of one or
more nicotine demethylase polypeptides may be obtained by
RNA interference by expression of a gene encoding a micro

fully complementary (i.e., 100% identical to the complement
of the target sequence) or partially complementary (i.e., less
than 100% identical to the complement of the target
sequence) to the target sequence.
Antisense suppression also can be used to inhibit the

RNA (miRNA). miRNAs are regulatory agents consisting of
about tWenty-tWo ribonucleotides. miRNA are highly e?i

expression of multiple proteins in the same plant (e.g., U.S.
Pat. No. 5,942,657). Furthermore, portions of the antisense
nucleotides may be used to disrupt the expression of the target
gene. Generally, sequences of at least 50 nucleic acids, 100,
200, 300, 400, 450, 500, 550 nucleic acids, or greater may be
used. Methods for using antisense suppression to inhibit the
expression of endogenous genes in plants are described, e.g.,
in Liu et al. (2002) Plant Physiol. 129:1732-1743; and Us.
Pat. Nos. 5,759,829 and 5,942,657; each of Which is incor
porated herein by reference as if set forth in its entirety.

cient at inhibiting the expression of endogenous genes. See,
e.g., Javier et al. (2003) Nature 425:257-263, incorporated
herein by reference as if set forth in its entirety.
For miRNA interference, the expression cassette is
designed to express an RNA molecule that is modeled on an

endogenous miRNA gene. The miRNA gene encodes an
RNA that forms a hairpin structure containing a 22-nucle

otide sequence that is complementary to another endogenous
20

lase polypeptide expression, the 22-nucleotide sequence is
selected from a cytochrome P450 polypeptide transcript
sequence and contains 22 nucleotides encoding this cyto

E?iciency of antisense suppression may be increased by
including a poly-dT region in the expression cassette at a
position 3' to the antisense sequence and 5' of the polyadeny

lation signal. See, US Patent Application Publication No.
2002/0048814, incorporated herein by reference as if set forth

gene (target sequence). For suppression of nicotine demethy

25

in its entirety.

chrome P450 polypeptide sequence in sense orientation and
21 nucleotides of a corresponding antisense sequence that is
complementary to the sense sequence. miRNA molecules are

For dsRNA interference, a sense RNA molecule like that

highly e?icient at inhibiting the expression of endogenous

described above for cosuppression and an antisense RNA
molecule that is fully or partially complementary to the sense
RNA molecule are expressed in the, same cell, resulting in

genes, and the RNA interference they induce is inherited by

subsequent generations of plants.
30

inhibition of the expression of the corresponding endogenous
messenger RNA. Expression of the sense and antisense mol
ecules can be accomplished by designing the expression cas
sette to comprise both a sense sequence and an antisense

sequence for the target cytochrome P450 sequence. Alterna
tively, separate expression cassettes may be used for the sense

35

Alternatively still, inhibition of the expression of one or
more cytochrome P450 polypeptides may be obtained by
hairpin RNA (hpRNA) interference or intron-containing hair
pin RNA (ihpRNA) interference. These methods are highly
e?icient at inhibiting the expression of endogenous genes.
See, Waterhouse & HelliWell (20013) Nat. Rev. Genet. 4:29
38 and the references cited therein.

and antisense sequences. Multiple plant lines transformed

The expression cassette for hpRNA interference may also

With the dsRNA interference expression cassette or expres
sion cassettes are then screened to identify plant lines that

be designed such that the sense sequence and the antisense
sequence do not correspond to an endogenous RNA in this
embodiment, the sense and antisense sequence ?ank a loop
sequence that comprises a nucleotide sequence correspond
ing to all or part of the endogenous messenger RNA of the

shoW the greatest inhibition of expression of the targeted
cytochrome P450 polypeptide. Methods for using dsRNA
interference to inhibit the expression of endogenous plant

40

genes are described in Waterhouse et al. (1998) Pros. Natl.

Acad. Sci. USA 95:13939-13964; Liu et al. (2002) Plant

Physiol. 129:1732'-1743; and International Patent Applica

45

rated herein by reference as if set forth in its entirety.

tion Publication Nos. WO 99/149024, WO 99/153050, WO
99/16163 1 and WO 00/149035; each of Which is incorpo
rated herein by reference as if set forth in its entirety.

Transcriptional gene silencing (TGS) may be accom
plished through use of hpRNA constructs Where the inverted
repeat of the hairpin shares sequence identity With the pro

Amplicon expression cassettes comprise a plant virus-de
rived sequence that contains all or part of the target gene but
generally not all of the genes of the native virus. The viral

target gene. Thus, it is the loop region that determines the
speci?city of the RNA interference. See, e.g., International
Patent Application Publication No. WO 02/00904, incorpo

50

moter region of a gene to be silenced. Processing of the
hpRNA into short RNAs that can interact With the homolo

sequences present in the transcription product of the expres

gous promoter region may trigger degradation or methylation

sion cassette alloW the transcription product to direct its oWn

to result in silencing (AufsatZ et al. (2002) Proc. Natl. Acad.
Sci. 99:16499-16506; and Mette et al. (2000) EMBO J.

replication. The transcripts produced by the amplicon may be
either sense or antisense relative to the target sequence (i.e.,

55

19:5194-5201).

the messenger RNA for a cytochrome P450 polypeptide that
is involved in the metabolic conversion of nicotine to norni

In some instances, the polynucleotide encodes an antibody
that binds to at least one cytochrome P450 polypeptide, and

cotine). Methods of using amplicons to inhibit the expression
of endogenous plant genes are described, e.g., in Angell &
Baulcombe (1997) EMBO .1. 16:3675-3684; Angell & Baul
combe (1999) Plant.]. 201357-362; and Us. Pat. No. 6,646,

reduces the activity of a cytochrome P450 polypeptide of the
present invention. In another embodiment, the binding of the
antibody results in increased turnover of the antibody-cyto

60

chrome P450 polypeptide complex by cellular quality control
mechanisms. The expression of antibodies in plant parts and
the inhibition of molecular pathWays by expression and bind
ing of antibodies to proteins in plant parts are Well knoWn in

805, each of Which is incorporated herein by reference as if set

forth in its entirety.
In some instances, the polynucleotide expressed by the
expression cassette of the invention is catalytic RNA or has

riboZyme activity speci?c for the messenger RNA of a cyto
chrome P450 polypeptide described herein. Thus, the poly

65

the art. See, e.g., Conrad & SonneWald (2003) Nature Bio
tech. 21 :35-36, incorporated herein by reference as if set forth

in its entirety.

US 8,124,851 B2
29

30

The activity of a cytochrome P450 polypeptide of the
present invention can be reduced or eliminated by disrupting
the gene encoding the cytochrome P450 polypeptide. The
gene encoding the cytochrome P450 polypeptide may be
disrupted by any method knoWn in the art, e. g., by transposon

believed that these sequences encode a nicotine demethylase

5

tagging or by mutageniZing plants using random or targeted
mutagenesis and selecting for plants that have reduced nico

lead to inhibition of gene function of this individual locus
may prove to be superior to those that inhibit the entire gene
family. The P450 enZymes are involved in many mechanisms
in the plant, the inhibition of Which may prove deleterious or

tine demethylase activity or mutations in CYP82E4v2 or
CYP82E5v2.
Transposon tagging may be used to reduce or eliminate the
activity of one or more cytochrome P450 polypeptides of the

detrimental to the groWth and development of the plant or
may negatively impact factors such as the disease defense

present invention. Transposon tagging comprises inserting a

capabilities of the plant. Likewise, because the Nicotiana
plant P450 enZymes have been implicated in plant metabo
lites such as phenylpropanoid, alkaloids, terpenoids, lipids,
cyanogenic glycosides, glucosinolates, and a host of other
chemical entities, disruption of P450 activity may alter com

transposon Within an endogenous cytochrome P450 gene to
reduce or eliminate expression of the cytochrome P450

polypeptide.
Methods for the transposon tagging of speci?c genes in
plants are Well knoWn in the art. See, e.g., Maes et al., (1999)

Trends Plant Sci. 4:90-96; Dharmapuri & Sonti (1999)
FEMSMicerobiol. Lett. 179:53-59; Meissner et al. (2000)
Plant.]. 22:265-274; Phogat et al. (2000) J Biosci. 25:57-63;
Walbot (2000) Curr. Opin. Plant Biol. 2:103-107; Gai et al.
(2000) Nucleic Acids Res. 28:94-96; and Fitzmaurice et al.

ponents involved in tobacco ?avor, texture, or other proper
ties that Would impact the commercial usefulness of the plant.
20

(1999) Genetics 153:1919-1928).
Additional methods for decreasing or eliminating the
expression of endogenous genes in plants are also knoWn in

that catalyZes the oxidative N-demethylation of nicotine to
nornicotine. Thus, methods to speci?cally inhibit these cod
ing sequences and not other P450 sequences may be bene?
cial to the recombinant plant. That is, strategies that Would

25

Therefore, the use of the methods discussed above to inhibit
expression in a manner that speci?cally targets the sequence

coding for SEQ ID NO:2 or 13 may be preferred, including
targeted mutational strategies, such as chimeraplasty. See,
e.g., SteWart et al. (2000) Biotechniques 24:838-843; and
Graham et al. (2002) Biochim BiophysActa 1587: 1-6; each of

These methods include other forms of mutagenesis, using

Which is incorporated herein by reference as if set forth in its
entirety. In some embodiments, the methods discussed above

mutagenic or carcinogenic compounds including ethyl meth
anesulfonate-induced mutagenesis, deletion mutagenesis,

targets SEQ ID NO:1 (encoding SEQ ID NO:2), SEQ ID

the art and can be similarly applied to the instant invention.

and fast neutron deletion mutagenesis used in a reverse genet

ics sense (With PCR) to identify plant lines in Which the
endogenous gene has been deleted. For examples of these
methods see, Ohshima et al. (1998) Wrology 213:472-481;
Okubara et al. (1994) Genetics 137:867-874; and Quesada et
al. (2000) Genetics 154:421-4315; each ofWhich is incorpo

are used to inhibit expression in a manner that speci?cally
30

sequences.

The compositions of the invention can be used in screening
methods to identify nonconverter plants for use in breeding
programs. In this manner, the nucleotide sequences of the
35

rated herein by reference as if set forth in its entirety. In
addition, a fast and automatable method for screening for

invention can be used to screen native germplasms for non
converter plants having a stable mutation in one or more P450

genes identi?ed herein. These nonconverter plants identi?ed
by the methods of the invention can be used to develop breed

chemically induced mutations, TILLING (Targeting Induced
Local Lesions In Genomes), using denaturing HPLC or selec
tive endonuclease digestion of selected PCR products is also
applicable to the instant invention. See, McCallum et al.

NO:50 (encoding SEQ ID NO: 13), or both of these

ing lines.
40

In addition to the nucleotide sequences encoding P450
coding sequences, compositions of the invention include an

(2000) Nat. Biotechnol. 18:455-457, herein incorporated by

intron sequence in the CYP82E5v2 sequence that can be used

reference.
Mutations that impact gene expression or that interfere

With the function of the encoded cytochrome P450 protein

in screening methods. While not intending to be bound by any
particular mechanism of action, the CYP82E5v2 gene(s) may
represent the only member(s) of the cytochrome P450 family

can be determined using methods that are Well knoWn in the
art. Insertional mutations in gene exons usually result in null
mutants. Mutations in conserved residues can be particularly

involved in the metabolic conversion of nicotine to nomico
tine (and as stated previously there is a good likelihood that
the CYP82E5v2 cDNAs originated from a single unique

genetic locus) in green-leaves of tobacco. For certain appli

effective in inhibiting the metabolic function of the encoded

protein. Conserved residues of plant cytochrome P450
polypeptides suitable for mutagenesis With the goal to elimi
nate activity of a cytochrome P450 polypeptide in converting

50

differentiating this speci?c member of the cytochrome P450
gene family from the rest of the closely related sequences
Within this family. For example, it is possible that Within the

nicotine to nornicotine in a Nicotiana plant or plant part have

naturally existing tobacco ger'mplasm (or in mutageniZed

been described. Conserved residues of plant cytochrome
P450 polypeptides are disclosed in FIG. lA-C, Where the
residues that differ from the other P450 polypeptides are
shaded in grey. The conserved residue is that Which is not
shaded in grey at each position. Such mutants can be isolated

55

according to Well-knoWn procedures.
Dominant mutants can be used to trigger RNA silencing
due to gene inversion and recombination of a duplicated gene

cations, it Would be useful to have a means of diagnostically

60

populations), accessions may exist in Which this gene is natu
rally dysfunctional and may therefore may be valuable as a
permanently nonconverter resource. Such dysfunctional
genes may include those encoding the polypeptides set forth
in SEQ ID NOS:6 and 12. A method to speci?cally assay for

such genotypes (e.g., deletion mutants, rearrangements, and
the like) could serve as a poWerful tool. The present invention

locus. See, e.g., Kusaba et al. (2003) Plant Cell 15:1455

includes primers designed to speci?cally amplify exon 1 and

1467.
While a number of sequences are recogniZed in the practice

exon 2 of CYP82E5v2 or CYP82E4v2 Where one of the tWo

of the invention, in particular sequences encoding SEQ ID
NO:2 and 13 ?nd particular use. While not intending to be

bound by any particular mechanism of action, the inventors

65

primer pairs corresponds to the intron betWeen the exons.
Examples of primers useful to amplify the exons of
CYP82E4v2 include SEQ ID NO:32 With SEQ ID NOS:33
35. Examples of primers useful to amplify the exons of
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CYP82E5v2 include SEQ ID NO136 With 37 and SEQ ID

(pollen); Kaeppler et al. (1 990) Plant CellReports 91415-418;

NO138 With 39. These same primers can be used for sequence

and Kaeppler et al. (1992) Theo}: Appl. Genet, 841560-566
(Whisker-mediated transformation); D’Halluin et al. (1992)

analysis of the products.

Plant Cell 411495-1505 (electroporation); each of Which is
incorporated herein by reference as if set forth in its entirety.

When any cDNA corresponding to a member of the
CYP82E2 family is used as a hybridization probe in a South
ern blotting assay of tobacco genome is DNA, a complex

Any plant tissue that can be subsequently propagated using
clonal methods Whether by organogenesis or embryogenesis,

pattern is observed. This is expected, given that there are

multiple, closely related members of this gene family.

may be transformed With a recombinant construct comprising
a cytochrome P450 inhibitory sequence, for example, an

Because the intron regions of genes are typically less con
served than exons, it is predicted that the use of an intron

expression cassette of the present invention. As used herein,

speci?c probe Would reduce this complexity and better enable

“organogenesis” means a process by Which shoots and roots
are developed sequentially from meristematic centers. As
used herein, “embryogenesis” means a process by Which
shoots and roots develop together in a concerted fashion (not
sequentially), Whether from somatic cells or gametes. Exem
plary tissues that are suitable for various transformation pro
tocols described herein include, but are not limited to, callus

one to distinguish the gene(s) corresponding to the
CYP82E4v2 gene or the CYP82E5v2 gene from the other
members of the family. The use of a CYP82E4v2 or

CYP82E5v2 intron-speci?c probe, and/or the PCR primers
used to generate products provide poWerful tools in assays to
determine Whether any naturally occurring, or mutageniZed,
tobacco plants possess deletions or rearrangements that may
render the gene inactive. Such a plant can then be used in
breeding programs to create tobacco lines that are incapable

tissue, existing meristematic tissue (e.g., apical meristems,
axillary buds and root ineristems) and induced meristem tis
20

of converting.
Transformed Plants, Plant Parts and Products Having

like.
As used herein, “stable transformation” means that the
nucleotide construct of interest introduced into a plant inte

Reduced Nornicotine and NNN Content

The cytochrome P450 polynucleotides of the invention,
and variants and fragments thereof, can be used in the meth
ods of the present invention to inhibit cvtochrome P450s that

sue (e.g., cotyledon meristem and hypocotyl meristem),
hypocotyls, cotyledons, leaf disks, pollen, embryos and the

25

grates into the genome of the plant and is capable of being
inherited by the progeny thereof. Likewise, “transient trans

are involved in the metabolic conversion of nicotine to nor

formation” means that a sequence is introduced into the plant

nicotine in a plant. In this manner, inhibitory sequences that
target expression or function of a cytochrome P450 polypep
tide disclosed herein are introduced into a plant or plant cell of
interest. The expression cassettes described herein can be
introduced into a plant of interest, for example, a Nicotiana
plant as noted herein beloW, using any suitable transformation
methods knoWn in the art including those described herein.
The methods of the invention do not depend on a particular
method for introducing a sequence into a plant or plant part,
only that the desired sequence gains access to the interior of at
least one cell of the plant or plant part. Methods for introduc
ing polynucleotide sequences into plants are knoWn in the art
and include, but are not limited to, stable transformation
methods, transient transformation methods and viral-medi
ated transformation methods.
Transformation protocols as Well as protocols for introduc

and is only temporally expressed or is only transiently present
in the plant.
30

The inhibitory sequences of the invention can be transiently
transformed into the plant using techniques knoWn in the art.
Such techniques include viral vector systems and the precipi
35

sequent release of the DNA. Thus, the transcription from the

40
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8315602-56116), A grobacterium-mediated transformation
(US. Pat. Nos. 5,104,310; 5,149,645; 5,177,010; 5,231,019;
5,463,174; 5,464,763; 5,469,976; 4,762,785; 5,004,863;
5,159,135; 5,563,055 and 5,981,840), direct gene transfer

tein encoded therein, involving viral DNA or RNA mol
ecules, are knoWn in the art. See, e.g., US. Pat. Nos. 5,889,

191; 5,889,190; 5,866,785; 5,589,367; 5,316,931; and Porta
et al. (1996) Molecular Biotechnology 51209-221; each of
Which is incorporated herein by reference as if set forth in its

entirety.

(PasZkoWski et al. (1984) EMBO .1. 112717-2722) and ballis
tic particle acceleration (US. Pat. Nos. 4,945,050; 5,141,131 ;
5,886,244; 5,879,918 and 5,932,782; Tomes et al. (1995) in
Plant cell, tissue, and organ culturefundamental methods, ed.
Gamborg & Phillips (Springer-Verlag, Berlin); McCabe et al.
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(1988) Biotechnology 61923-926). See also, Weissinger et al.

60

Wet et al. (1985) in The experimental manipulation ofovule
tissues, ed. Chapman et al. (Longman, N.Y.); pp. 197-209

rating an expression cassette of the invention Within a viral
DNA or RNA molecule. Promoters for use in the expression
cassettes of the invention also encompass promoters utiliZed

for transcription by viral RNA polymerases. Methods for
introducing polynucleotides into plants and expressing a pro

electroporation (Shillito et al. (1987) Meth. Enzymol. 153:

(1988) Ann. Rev. Genet. 221421-477; Christou et al. (1988)
Plant Physiol. 871671-674 (soybean); McCabe et al. (1988)
Bio/Technology 61923-926 (soybean); Finer & McMullen
(1991) In VlZI’O CellDev. Biol. 27P1175-182 (soybean); Singh
et al. (1998) Theor. Appl. Genet. 961319-324 (soybean); De

With polyethyenlimine (PEI; Sigma 4P3143).
Alternatively, the inhibitory sequence of the invention may
be introduced into plants by contacting plants With a virus or
viral nucleic acids. Generally, such methods involve incorpo

injection (CrossWay et al. (1986) Biotechniques 41320-334),
313-336; and Riggs et al. (1986) Proc. Natl. Acad Sci. USA

tation of the polynucleotide in a manner that precludes sub

particle-bound DNA can occur, but the frequency With Which
it is released to become integrated into the genome is greatly
reduced. Such methods include the use of particles coated

ing heterologous polynucleotide sequences into plants vary
depending on the type of plant or plant cell targeted for
transformation. Suitable methods of introducing polynucle
otides into plant cells of the present invention include micro

The inhibitory sequences of the invention can be provided
to a plant using a variety of transient transformation methods.

Transformed cells may be groWn into Nicotiana plants in
accordance With conventional methods. See, e.g., Vasil &

Hildebrandt (1965) Science 1501889; Negaard & Hoffman

(1989) Biotechniques 7(8)1808-812. These plants may then
be groWn, and either pollinated With the same transformed

line or different lines, and the resulting progeny having

expression of the desired phenotypic characteristic identi?ed,
i.e., reduced expression of one or more nicotine demethylases
that are involved in the metabolic conversion of nicotine to
nornicotine, and thus reduced content of nornicotine, and a
65

concomitant reduced content of its nitrosamine metabolite,
NNN, in the plant, particularly in the leaf tissues. TWo or more
generations may be groWn to ensure that expression of the

